{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [],
   "source": [
    "#Note: While PDF files are great for laying out text in a way that’s easy for people\n",
    "#to print and read, they’re not straightforward for software to parse into plaintext. \n",
    "#As such, PyPDF2 might make mistakes when extracting text from a PDF and may even be\n",
    "#unable to open some PDFs at all. There isn’t much you can do about this, unfortunately. PyPDF2 may simply be unable to work with some of your particular PDF files."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {},
   "outputs": [],
   "source": [
    "# importing the required modules \n",
    "import PyPDF2\n",
    "from PyPDF2 import PdfFileReader\n",
    "from textacy import preprocessing\n",
    "import ftfy\n",
    "import textacy\n",
    "from textacy import preprocessing"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {},
   "outputs": [],
   "source": [
    "# creating a pdf File object of original pdf \n",
    "pdfFileObj = open('data/4.pdf', 'rb') \n",
    "\n",
    "# creating a pdf Reader object \n",
    "pdfReader = PyPDF2.PdfFileReader(pdfFileObj) "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {},
   "outputs": [],
   "source": [
    "pdf_text = ''\n",
    "for i in range(0, pdfReader.numPages):\n",
    "    pageObj = pdfReader.getPage(i)\n",
    "    page = pageObj.extractText()\n",
    "    pdf_text = pdf_text + ' ' + page "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "metadata": {
    "scrolled": false
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      " n engl j med   \n",
      "nejm.org 1From Brigham and Women™s Hospital \n",
      "Heart and Vascular Center and Harvard \n",
      "Medical School, Boston (M.R.M.); Surgi\n",
      "-sphere, Chicago (S.S.D.); Baylor College of \n",
      "Medicine and Department of Veterans Af\n",
      "-fairs, Houston (S.K.); Christ Hospital, Cin\n",
      "-cinnati (T.D.H.); the Department of Bio\n",
      "-medical Engineering, University of Utah, \n",
      "Salt Lake City (A.N.P.); and HCA Research \n",
      "Institute, Nashville (A.N.P.). Address re\n",
      "-print requests to Dr. Mehra at Brigham \n",
      "and Women™s Hospital, 75 Francis St., \n",
      "Boston, MA 02115, or at \n",
      " \n",
      "mmehra@\n",
      "  \n",
      "\n",
      "bwh\n",
      " . harvard\n",
      " . edu.\n",
      "This article was published on May 1, 2020, \n",
      "and updated on May 8, 2020, at NEJM.org.\n",
      "DOI:˜10.1056/NEJMoa2007621\n",
      "Copyright © 2020 Massachusetts Medical Society.BACKGROUND\n",
      "Coronavirus disease 2019 (Covid-19) may disproportionately affect people with \n",
      "cardiovascular disease. Concern has been aroused regarding a potential harmful \n",
      "effect of angiotensin-convertingŒenzyme (ACE) inhibitors and angiotensin-recep\n",
      "-tor blockers (ARBs) in this clinical context.\n",
      "METHODS\n",
      "Using an observational database from 169 hospitals in Asia, Europe, and North \n",
      "America, we evaluated the relationship of cardiovascular disease and drug therapy \n",
      "with in-hospital death among hospitalized patients with Covid-19 who were admit\n",
      "-ted between December 20, 2019, and March 15, 2020, and were recorded in the \n",
      "Surgical Outcomes Collaborative registry as having either died in the hospital or \n",
      "survived to discharge as of March 28, 2020.\n",
      "RESULTS\n",
      "Of the 8910 patients with Covid-19 for whom discharge status was available at the \n",
      "time of the analysis, a total of 515 died in the hospital (5.8%) and 8395 survived \n",
      "to discharge. The factors we found to be independently associated with an in\n",
      "-creased risk of in-hospital death were an age greater than 65 years (mortality of \n",
      "10.0%, vs. 4.9% among those ˜65 years of age; odds ratio, 1.93; 95% confidence \n",
      "interval [CI], 1.60 to 2.41), coronary artery disease (10.2%, vs. 5.2% among those \n",
      "without disease; odds ratio, 2.70; 95% CI, 2.08 to 3.51), heart failure (15.3%, vs. \n",
      "5.6% among those without heart failure; odds ratio, 2.48; 95% CI, 1.62 to 3.79), \n",
      "cardiac arrhythmia (11.5%, vs. 5.6% among those without arrhythmia; odds ratio, \n",
      "1.95; 95% CI, 1.33 to 2.86), chronic obstructive pulmonary disease (14.2%, vs. \n",
      "5.6% among those without disease; odds ratio, 2.96; 95% CI, 2.00 to 4.40), and \n",
      "current smoking (9.4%, vs. 5.6% among former smokers or nonsmokers; odds \n",
      "ratio, 1.79; 95% CI, 1.29 to 2.47). No increased risk of in-hospital death was found \n",
      "to be associated with the use of ACE inhibitors (2.1% vs. 6.1%; odds ratio, 0.33; \n",
      "95% CI, 0.20 to 0.54) or the use of ARBs (6.8% vs. 5.7%; odds ratio, 1.23; 95% CI, \n",
      "0.87 to 1.74).\n",
      "CONCLUSIONS\n",
      "Our study confirmed previous observations suggesting that underlying cardiovascu\n",
      "-lar disease is associated with an increased risk of in-hospital death among patients \n",
      "hospitalized with Covid-19. Our results did not confirm previous concerns regarding \n",
      "a potential harmful association of ACE inhibitors or ARBs with in-hospital death in \n",
      "this clinical context. (Funded by the William Harvey Distinguished Chair in Ad\n",
      "-vanced Cardiovascular Medicine at Brigham and Women™s Hospital.)\n",
      "ABSTRACT\n",
      "Cardiovascular Disease, Drug Therapy,  and Mortality in Covid-19Mandeep R. Mehra, M.D., Sapan\n",
      " S. Desai, M.D., Ph.D., \n",
      "SreyRam Kuy, M.D., M.H.S., Timothy\n",
      " D. Henry, M.D., and Amit\n",
      " N. Patel, M.D.\n",
      "  \n",
      "Original Article\n",
      " n engl j med   \n",
      "nejm.org 2The\n",
      " new england journal \n",
      "of medicine\n",
      "As the coronavirus disease 2019 \n",
      "(Covid-19) pandemic has spread around \n",
      "the globe, there has been growing recog\n",
      "-nition that persons with underlying increased \n",
      "cardiovascular risk may be disproportionately \n",
      "affected.\n",
      "1-3\n",
      " Several studies of case series have \n",
      "noted cardiac arrhythmias, cardiomyopathy, and \n",
      "cardiac arrest as terminal events in patients with \n",
      "Covid-19.\n",
      "1-4\n",
      " Higher incidences of cardiac arrhyth\n",
      "-mias, acute coronary syndromes, and heart fail\n",
      "-ureŒrelated events have also been reported during \n",
      "seasonal influenza outbreaks, which suggests that \n",
      "acute respiratory infections may result in activa\n",
      "-tion of coagulation pathways, proinflammatory \n",
      "effects, and endothelial cell dysfunction.\n",
      "5 In ad\n",
      "-dition, however, concern has been expressed that \n",
      "medical therapy for cardiovascular disease might \n",
      "specifically contribute to the severity of illness \n",
      "in patients with Covid-19.\n",
      "6,7\n",
      "Severe acute respiratory syndrome coronavirus \n",
      "2 (SARS-CoV-2), the causative agent of Covid-19, \n",
      "has been shown to establish itself in the host \n",
      "through the use of angiotensin-converting en\n",
      "-zyme 2 (ACE2) as its cellular receptor.\n",
      "8 ACE2 is \n",
      "a membrane-bound monocarboxypeptidase found \n",
      "ubiquitously in humans and expressed predomi\n",
      "-nantly in heart, intestine, kidney, and pulmonary \n",
      "alveolar (type II) cells.\n",
      "7,9\n",
      " Entry of SARS-CoV-2 \n",
      "into human cells is facilitated by the interaction \n",
      "of a receptor-binding domain in its viral spike \n",
      "glycoprotein ectodomain with the ACE2 receptor.\n",
      "10ACE2 is counterregulatory to the activity of \n",
      "angiotensin II generated through ACE1 and is \n",
      "protective against detrimental activation of the \n",
      "reninŒangiotensinŒaldosterone system. Angioten\n",
      "-sin II is catalyzed by ACE2 to angiotensin-(1Œ7), \n",
      "which exerts vasodilatory, antiinflammatory, an\n",
      "-tifibrotic, and antigrowth effects.\n",
      "11 It has been \n",
      "suggested that ACE inhibitors and angiotensin-\n",
      "receptor blockers (ARBs) may increase the expres\n",
      "-sion of ACE2, which has been shown in the heart \n",
      "in rats,\n",
      "12 and thereby may confer a predisposition \n",
      "to more severe infection and adverse outcomes \n",
      "during Covid-19.\n",
      "6,7\n",
      " Others have suggested that \n",
      "ACE inhibitors may counter the antiinflammatory \n",
      "effects of ACE2. However, in vitro studies have \n",
      "not shown direct inhibitory activity of ACE in\n",
      "-hibitors against ACE2 function.\n",
      "9,13\n",
      "Despite these uncertainties, some have rec\n",
      "-ommended cessation of treatment with ACE in\n",
      "-hibitors and ARBs in patients with Covid-19.\n",
      "6 However, several scientific societies, including \n",
      "the American Heart Association, the American \n",
      "College of Cardiology, the Heart Failure Society \n",
      "of America, and the Council on Hypertension of \n",
      "the European Society of Cardiology, have urged \n",
      "that these important medications should not be \n",
      "discontinued in the absence of clear clinical evi\n",
      "-dence of harm.\n",
      "14,15\n",
      " We therefore undertook a study \n",
      "to investigate the relationship between underlying \n",
      "cardiovascular disease and Covid-19 outcomes and \n",
      "to evaluate the association between cardiovascular \n",
      "drug therapy and mortality in this illness.\n",
      "Methods\n",
      "Data Source\n",
      "We analyzed deidentified data from the Surgical \n",
      "Outcomes Collaborative (Surgisphere), an interna\n",
      "-tional registry. Our analysis included data from \n",
      "169 hospitals located in 11 countries in Asia, \n",
      "Europe, and North America. The collaborative uses \n",
      "automated extraction of data from inpatient and \n",
      "outpatient electronic health records, supply-chain \n",
      "databases, and financial records, combined with \n",
      "point-of-care data entry for procedures. A manual \n",
      "data-entry process is used for quality assurance \n",
      "and validation. Data are collected through auto\n",
      "-mated data transfers that capture information \n",
      "from each health care entity at regular intervals \n",
      "on a prospective, ongoing basis. Verifiable source \n",
      "documentation for the data elements includes elec\n",
      "-tronic inpatient and outpatient medical records.\n",
      "Data acquisition is facilitated through the use \n",
      "of a standardized Health Level SevenŒcompliant \n",
      "data dictionary. After this data dictionary is har\n",
      "-monized with data from electronic health records, \n",
      "the majority of the data acquisition is completed \n",
      "with automated interfaces. The collected data \n",
      "sample from each health care entity is validated \n",
      "against financial records and external databas\n",
      "-es. All protected health information is stripped \n",
      "from each record before storage in a cloud-based \n",
      "data warehouse. The collaborative is compliant \n",
      "with the Agency for Healthcare Research and \n",
      "Quality guidelines for registries and the Food and \n",
      "Drug Administration guidance on real-world evi\n",
      "-dence. The collection and analysis of data in the \n",
      "registry have been deemed exempt from ethics \n",
      "review.\n",
      "Data Collection\n",
      "The collaborative registry was used as a resource \n",
      "to analyze data from all patients with polymerase-\n",
      " n engl j med   \n",
      "nejm.org 3Cardiovascular Disease in Covid-19\n",
      "chain-reaction (PCR)Œproven Covid-19 who were \n",
      "admitted to the hospital between December 20, \n",
      "2019, and March 15, 2020, and who were re\n",
      "-corded in the registry as having either died in \n",
      "the hospital or survived to hospital discharge as \n",
      "of March 28, 2020. Data from the registry can be \n",
      "analyzed only after a patient™s hospitalization is \n",
      "complete, and therefore our sample did not in\n",
      "-clude patients who were admitted to the hospital \n",
      "during this time window but were still hospital\n",
      "-ized at the end of it. Our sample also may have \n",
      "excluded some patients who had died or were \n",
      "discharged by March 28 but whose discharge \n",
      "status had not yet been recorded by the hospital.\n",
      "The presence in the record of a positive labo\n",
      "-ratory finding confirming SARS-CoV-2 infection \n",
      "was used for classifying a patient as positive for \n",
      "Covid-19. A positive laboratory finding for SARS-\n",
      "CoV-2 was defined as a positive result on high-\n",
      "throughput sequencing or real-time reverse-tran\n",
      "-scriptaseŒPCR (RT-PCR) assay of nasal or \n",
      "pharyngeal swab specimens. At each site, Covid-19 \n",
      "was diagnosed on the basis of the World Health \n",
      "Organization guidance.\n",
      "16 Patients who did not \n",
      "undergo testing, had no record of testing in the \n",
      "collaborative database, or had a negative test \n",
      "were not included in the present study. For this \n",
      "study, only one positive test was necessary for \n",
      "the patient to be included in the analysis.\n",
      "Data on patients™ demographic characteris\n",
      "-tics, coexisting conditions (based on codes from \n",
      "the \n",
      "International Classification of Diseases, 10th Revi\n",
      "-sion, Clinical Modification\n",
      "), and cardiovascular drug \n",
      "therapy were included in this analysis. Clinical \n",
      "information included age, sex, continent of ori\n",
      "-gin, and underlying coexisting conditions as \n",
      "noted in either the inpatient or the outpatient \n",
      "electronic health record. Coexisting conditions \n",
      "included chronic obstructive pulmonary disease \n",
      "(COPD), an immunosuppressed condition (glu\n",
      "-cocorticoid use, a preexisting immunologic con\n",
      "-dition, or ongoing chemotherapy in patients \n",
      "with cancer), current or remote history of smok\n",
      "-ing, and a history of hypertension, diabetes mel\n",
      "-litus, hyperlipidemia, or underlying cardiovascu\n",
      "-lar disease (including coronary artery disease, \n",
      "heart failure, and cardiac arrhythmia). Cardio\n",
      "-vascular drug therapy recorded at the time of \n",
      "hospital admission was also included, including \n",
      "any antiplatelet therapy, use of insulin or other \n",
      "hypoglycemic agents, beta-blockers, statins, ARBs, \n",
      "and ACE inhibitors.\n",
      "All the authors reviewed the manuscript and \n",
      "vouch for the accuracy and completeness of the \n",
      "data provided.\n",
      "Statistical Analysis\n",
      "The primary analysis was an evaluation of the \n",
      "relationship of preexisting cardiovascular dis\n",
      "-ease and drug therapy with the end point of in-\n",
      "hospital death while controlling for confound\n",
      "-ers, including demographic characteristics and \n",
      "coexisting conditions. Categorical variables are \n",
      "shown as frequencies and percentages, and con\n",
      "-tinuous variables as means and standard devia\n",
      "-tions. Independent sample t-tests were complet\n",
      "-ed, and point differences with 95% confidence \n",
      "intervals are reported for all comparisons be\n",
      "-tween variables. Multiple imputation for missing \n",
      "values was not possible because for disease and \n",
      "drug variables there were no codes to indicate \n",
      "that data were missing; if the patient™s elec\n",
      "-tronic health record did not include information \n",
      "on a clinical characteristic, such as hyperlipid\n",
      "-emia or the use of beta-blockers, it was assumed \n",
      "that that characteristic was not present.\n",
      "A multivariable logistic-regression analysis \n",
      "was performed to ascertain the effects of age, \n",
      "race, coexisting conditions (coronary artery dis\n",
      "-ease, congestive heart failure, cardiac arrhyth\n",
      "-mia, diabetes mellitus, COPD, current smoking, \n",
      "former smoking, hypertension, immunocompro\n",
      "-mised state, and hyperlipidemia), hospital loca\n",
      "-tion (according to country), and medications \n",
      "(ACE inhibitors, ARBs, beta-blockers, antiplate\n",
      "-let agents, statins, insulin, and oral hypoglyce\n",
      "-mic agents) on the likelihood of in-hospital \n",
      "death. Linearity of the continuous variables with \n",
      "respect to the logit of the dependent variable was \n",
      "confirmed. Odds ratios and corresponding 95% \n",
      "confidence intervals were calculated. Separate \n",
      "age- and sex-adjusted analyses were also per\n",
      "-formed. The 95% confidence intervals have not \n",
      "been adjusted for multiple testing and should \n",
      "not be used to infer definitive effects.\n",
      "On the basis of the results of the initial \n",
      "analyses, additional analyses were performed to \n",
      "examine the robustness of the estimates initially \n",
      "obtained. Analyses according to continent of ori\n",
      "-gin as well as country classification (as either high \n",
      "income or lowŒmiddle income) were performed. \n",
      "A tipping-point analysis (an analysis that shows \n",
      "the effect size and prevalence of an unmeasured \n",
      "confounder that could shift the upper boundary \n",
      " n engl j med   \n",
      "nejm.org 4The\n",
      " new england journal \n",
      "of medicine\n",
      "of the confidence interval toward null) was per\n",
      "-formed. In addition, we sought to determine \n",
      "whether the effect of ACE inhibitors and statins \n",
      "noted in the overall study was also seen when \n",
      "the analysis was confined to a subgroup of pa\n",
      "-tients who might have an indication for these \n",
      "agents. Thus, the association of ACE inhibitor \n",
      "use with in-hospital death was examined in the \n",
      "subgroup of patients with hypertension, and the \n",
      "association of statin use with in-hospital death \n",
      "was examined in the subgroup of patients with \n",
      "hyperlipidemia, with the use of age- and sex-\n",
      "adjusted logistic-regression analysis. All statistical \n",
      "analyses were performed with R software, version \n",
      "3.6.3 (R Foundation for Statistical Computing), \n",
      "and SPSS Statistics software, version 26 (IBM).\n",
      "Results\n",
      "Patients\n",
      "Our study population included 8910 hospitalized \n",
      "patients from 169 hospitals who had Covid-19, \n",
      "who were admitted between December 20, 2019, \n",
      "and March 15, 2020, and who completed their \n",
      "hospital course (discharged alive or died) by March \n",
      "28, 2020. Patients who were hospitalized during \n",
      "this time without a completed course could not \n",
      "be included in the analysis. Our sample was \n",
      "made up of 1536 patients (17.2%) from North \n",
      "America, 5755 (64.6%) from Europe, and 1619 \n",
      "(18.2%) from Asia (details of the study popula\n",
      "-tion according to continent, country, and num\n",
      "-ber of hospitals are provided in Table S1 in the \n",
      "Supplementary Appendix, available with the full \n",
      "text of this article at NEJM.org). The mean (±SD) \n",
      "age was 49±16 years (16.5% of the patients were \n",
      ">65 years of age), 40.0% of the patients were \n",
      "women, 63.5% were white, 7.9% were black, 6.3% \n",
      "were Hispanic, and 19.3% were Asian.\n",
      "With respect to cardiovascular risk factors, \n",
      "30.5% of the patients had hyperlipidemia, 26.3% \n",
      "had hypertension, 14.3% had diabetes mellitus, \n",
      "16.8% were former smokers, and 5.5% were cur\n",
      "-rent smokers. Preexisting cardiovascular disease \n",
      "in this sample included coronary artery disease \n",
      "(present in 11.3% of the patients), a history of con\n",
      "-gestive heart failure (2.1%), and a history of cardiac \n",
      "arrhythmia (3.4%). Other coexisting conditions \n",
      "included COPD (in 2.5% of the patients) and an \n",
      "underlying immunosuppressed condition (2.8%). \n",
      "Medical therapy included ACE inhibitors (8.6% \n",
      "of the patients), ARBs (6.2%), statins (9.7%), \n",
      "beta-blockers (5.9%), and antiplatelet agents (3.3%). \n",
      "Insulin was used in 3.4% of the patients, and \n",
      "other hypoglycemic agents were used in 9.6%. \n",
      "The mean length of hospital stay was 10.7±2.7 \n",
      "days, with an overall in-hospital mortality of \n",
      "5.8% (515 of 8910 patients) in this population of \n",
      "patients with completed outcomes. Of the pa\n",
      "-tients who had been admitted to an intensive care \n",
      "unit (ICU) at any time during their hospitaliza\n",
      "-tion, 24.7% died, as compared with 4.0% of the \n",
      "patients who had not been admitted to an ICU.\n",
      "Analysis of Survivors as Compared \n",
      " with Nonsurvivors\n",
      "Table\n",
      " 1 shows the distribution of demographic \n",
      "characteristics and coexisting conditions among \n",
      "survivors and nonsurvivors, along with the be\n",
      "-tween-group differences and 95% confidence in\n",
      "-tervals. Nonsurvivors were older, more likely to be \n",
      "white, and more often men, and they had a \n",
      "greater prevalence of diabetes mellitus, hyperlip\n",
      "-idemia, coronary artery disease, heart failure, \n",
      "and cardiac arrhythmias. Patients who died were \n",
      "also more likely to have had COPD and a history \n",
      "of current smoking. Among medications, ACE in\n",
      "-hibitors and statins were more commonly used by \n",
      "survivors than by nonsurvivors (Table\n",
      " 2), whereas \n",
      "no association between survival and the use of \n",
      "ARBs was found. The length of hospital stay dif\n",
      "-fered between survivors and nonsurvivors (10.5±2.5 \n",
      "days vs. 7.5±2.8 days). When the data were ana\n",
      "-lyzed according to age decile, continent, or in\n",
      "-come category of the country in which the hos\n",
      "-pital was located (high income or lowŒmiddle \n",
      "income), the results were similar (Fig. S1 and \n",
      "Tables S2 and S3).\n",
      "Multivariable Logistic-Regression Analysis\n",
      "A multivariable logistic-regression model was \n",
      "developed. Independent predictors of in-hospital \n",
      "death and their corresponding odds ratios and \n",
      "95% confidence intervals are shown in Figure\n",
      " 1. \n",
      "An age greater than 65 years, coronary artery \n",
      "disease, congestive heart failure, cardiac arrhyth\n",
      "-mia, COPD, and current smoking were associat\n",
      "-ed with a higher risk of in-hospital death. Fe\n",
      "-male sex, the use of ACE inhibitors, and the use \n",
      "of statins were associated with a better chance \n",
      "of survival to hospital discharge, with no associa\n",
      "-tion found for the use of ARBs. For female sex, \n",
      " n engl j med   \n",
      "nejm.org 5Cardiovascular Disease in Covid-19\n",
      "the odds ratio for dying in the hospital was 0.79 \n",
      "(95% confidence interval [CI], 0.65 to 0.95); for \n",
      "ACE inhibitor use, the odds ratio was 0.33 (95% \n",
      "CI, 0.20 to 0.54); and for statin use, the odds \n",
      "ratio was 0.35 (95% CI, 0.24 to 0.52). For ARB \n",
      "use, the odds ratio was 1.23 (95% CI, 0.87 to \n",
      "1.74). The presence or absence of an immuno\n",
      "-suppressed condition, the race or ethnic group, \n",
      "and the presence or absence of hyperlipidemia \n",
      "or diabetes mellitus were not independent pre\n",
      "-dictors of death in the hospital. The analyses \n",
      "according to continent and according to the in\n",
      "-come category of the country (high or lowŒmiddle) \n",
      "were consistent with the overall results (Tables \n",
      "S4 and S5). Data from the age- and sex-adjusted \n",
      "multivariable logistic-regression analyses are \n",
      "shown in Table S6.\n",
      "Table˜1.\n",
      "˜Demographic˜Characteristics˜and˜Coexisting˜Conditions˜among˜Survivors˜and˜Nonsurvivors˜of˜Covid-19.*\n",
      "Characteristic˜or˜Condition\n",
      "Survivors˜(N˜=˜8395)Nonsurvivors˜(N˜=˜515)Difference˜(95%˜CI)ƒ\n",
      "Age Š yr\n",
      "48.7±16.655.8±15.1˜7.1 (˜8.4 to ˜5.7)\n",
      "Age >65 yr Š no. (%)\n",
      "1327 (15.8)\n",
      "147 (28.5)\n",
      "˜12.7 (˜16.0 to ˜9.4)\n",
      "Female sex Š no. (%)\n",
      "3392 (40.4)\n",
      "179 (34.8)\n",
      "5.6 (1.3 to 10.0)\n",
      "Race or ethnic group Š no. (%)⁄\n",
      "White5306 (63.2)\n",
      "351 (68.2)\n",
      "˜5.0 (˜9.1 to ˜0.8)\n",
      "Black672 (8.0)\n",
      "34 (6.6)\n",
      "1.4 (˜0.8 to 3.6)\n",
      "Hispanic529 (6.3)\n",
      "32 (6.2)\n",
      "0.1 (˜2.0 to 2.3)\n",
      "Asian1637 (19.5)\n",
      "84 (16.3)\n",
      "3.2 (˜0.2 to 6.5)\n",
      "Native American\n",
      "34 (0.4)\n",
      "1 (0.2)\n",
      "0.2 (˜0.3 to 0.8)\n",
      "Other219 (2.6)\n",
      "13 (2.5)\n",
      "0.1 (˜1.4 to 1.4)\n",
      "Coexisting conditions Š no. (%)\n",
      "Coronary artery disease\n",
      "907 (10.8)\n",
      "103 (20.0)\n",
      "˜9.2 (˜12.8 to ˜5.7)\n",
      "Congestive heart failure\n",
      "160 (1.9)\n",
      "29 (5.6)\n",
      "˜3.7 (˜5.8 to ˜1.8)\n",
      "Cardiac arrhythmia269 (3.2)\n",
      "35 (6.8)\n",
      "˜3.6 (˜5.8 to ˜1.4)\n",
      "Diabetes mellitus\n",
      "1175 (14.0)\n",
      "97 (18.8)\n",
      "˜4.8 (˜8.3 to ˜1.3)\n",
      "Hypertension2216 (26.4)\n",
      "130 (25.2)\n",
      "1.2 (˜2.8 to 5.1)\n",
      "Hyperlipidemia2535 (30.2)\n",
      "180 (35.0)\n",
      "˜4.8 (˜9.0 to ˜0.5)\n",
      "COPD193 (2.3)\n",
      "32 (6.2)\n",
      "˜3.9 (˜6.1 to ˜1.8)\n",
      "Current smoker\n",
      "445 (5.3)\n",
      "46 (8.9)\n",
      "˜3.6 (˜6.2 to ˜1.1)\n",
      "Former smoker\n",
      "1410 (16.8)\n",
      "83 (16.1)\n",
      "0.7 (˜2.6 to 4.0)\n",
      "Immunosuppressed condition\n",
      "227 (2.7)\n",
      "22 (4.3)\n",
      "˜1.6 (˜3.4 to 0.2)\n",
      "*  \n",
      "PlusŒminus values are means ±SD. The 95% confidence intervals (CIs) have not been adjusted for multiple testing and should not be used to infer definitive effects. COPD denotes chronic obstructive pulmonary disease, and Covid-19 coro-navirus disease 2019.ƒ  \n",
      "For mean age, the difference is given in years; for all other characteristics, the difference is given in percentage points.⁄  \n",
      "Race and ethnic group were reported by the patient.Table˜2.\n",
      "˜Cardiovascular˜Drug˜Therapy˜at˜Hospitalization˜among˜Survivors˜\n",
      "˜and˜Nonsurvivors˜of˜Covid-19.*\n",
      "Drug˜Class\n",
      "Survivors˜(N˜=˜8395)Nonsurvivors˜(N˜=˜515)Difference˜(95%˜CI)\n",
      "number (percent)\n",
      "percentage points\n",
      "ACE inhibitor\n",
      "754 (9.0)\n",
      "16 (3.1)\n",
      "5.9 (4.3 to 7.5)\n",
      "ARB518 (6.2)\n",
      "38 (7.4)\n",
      "˜1.2 (˜3.5 to 1.1)\n",
      "Beta-blocker497 (5.9)\n",
      "28 (5.4)\n",
      "0.5 (˜1.6 to 2.6)\n",
      "Antiplatelet282 (3.4)\n",
      "13 (2.5)\n",
      "0.8 (˜0.6 to 2.2)\n",
      "Statin824 (9.8)\n",
      "36 (7.0)\n",
      "2.8 (0.5 to 5.1)\n",
      "Insulin279 (3.3)\n",
      "23 (4.5)\n",
      "˜1.2 (˜3.0 to 0.7)\n",
      "Other hypoglycemic agent792 (9.4)\n",
      "59 (11.5)\n",
      "˜2.1 (˜4.9 to 0.8)\n",
      "*  \n",
      "The 95% confidence intervals have not been adjusted for multiple testing and should not be used to infer definitive effects. ACE denotes angiotensin-converting enzyme, and ARB angiotensin-receptor blocker. n engl j med   \n",
      "nejm.org 6The\n",
      " new england journal \n",
      "of medicine\n",
      "Additional Analyses\n",
      "In the tipping-point analysis to assess the poten\n",
      "-tial effect of an unmeasured confounder, it was \n",
      "estimated that a hypothetical unobserved binary \n",
      "confounder with a prevalence of 10% in the study \n",
      "population would need to have an odds ratio of \n",
      "at least 10 in order for the observed associations \n",
      "for either ACE inhibitors or statins to have 95% \n",
      "confidence intervals crossing the odds ratio \n",
      "boundary of 1.0 (Table S7). We also separately \n",
      "examined the interaction of ACE inhibitor use \n",
      "with mortality in the subgroup with hyperten\n",
      "-sion and the interaction of statin use with mor\n",
      "-tality in the subgroup with hyperlipidemia. These \n",
      "analyses, shown in Table S8, are consistent with \n",
      "the results of the primary analysis.\n",
      "Discussion\n",
      "Our investigation confirms previous reports of \n",
      "the independent relationship of older age, under\n",
      "-lying cardiovascular disease (coronary artery dis\n",
      "-ease, heart failure, and cardiac arrhythmias), cur\n",
      "-rent smoking, and COPD with death in Covid-19. \n",
      "Our results also suggest that women are propor\n",
      "-tionately more likely than men to survive the \n",
      "infection. Neither harmful nor beneficial asso\n",
      "-ciations were noted for antiplatelet therapy, beta-\n",
      "blockers, or hypoglycemic therapy. It is important \n",
      "to note that we were not able to confirm previous \n",
      "concerns regarding a potential harmful associa\n",
      "-tion of either ACE inhibitors or ARBs with in-\n",
      "hospital mortality in this clinical context.\n",
      "In viral infections such as influenza, older \n",
      "age is associated with an increased risk of car\n",
      "-diovascular events and death.\n",
      "5 In the 2003 epi\n",
      "-demic of severe acute respiratory syndrome \n",
      "(SARS, caused by SARS-CoV-1 infection), sex \n",
      "differences in the risk of death similar to those \n",
      "we observed were noted.\n",
      "17 Women have stronger \n",
      "innate and adaptive immunity and greater resis\n",
      "-tance to viral infections than men.\n",
      "18 In animal \n",
      "models of SARS-CoV-1 infection, higher suscep\n",
      "-tibility of male mice to SARS-CoV-1 and greater \n",
      "accumulation of macrophages and neutrophils \n",
      "in the lungs have been described.\n",
      "19 Ovariectomy \n",
      "or the use of estrogen-receptor antagonists \n",
      "increased mortality from SARS-CoV-1 infection \n",
      "in female animals. Furthermore, the difference in \n",
      "risk between the sexes increased with advancing \n",
      "age.\n",
      "19 These findings may support the observa\n",
      "-tion in our investigation that suggested an as\n",
      "-sociation between survival and female sex, inde\n",
      "-pendent of older age.\n",
      "Infection with SARS-CoV-2 is a mild disease \n",
      "in most people, but in some the disease pro\n",
      "-gresses to a severe respiratory illness character\n",
      "-ized by a hyperinflammatory syndrome, multi\n",
      "-organ dysfunction, and death.\n",
      "20 In the lung, the \n",
      "viral spike glycoprotein of SARS-CoV-2 interacts \n",
      "with cell-surface ACE2, and the virus is internal\n",
      "-ized by endocytosis. The endocytic event up-\n",
      "regulates the activity of ADAM metallopeptidase \n",
      "domain 17 (ADAM17), which cleaves ACE2 from \n",
      "the cell membrane, resulting in a loss of ACE2-\n",
      "mediated protection against the effects of activa\n",
      "-Figure˜1.\n",
      "˜Independent˜Predictors˜of˜In-Hospital˜Death˜from˜Multivariable˜Logistic-Regression˜Analysis.\n",
      "Numbers and percentages of patients with each risk factor who died (risk factor present) and of patients without each risk factor who \n",
      "died (risk factor absent) are shown. The 95% confidence intervals (CIs) of the odds ratios have not been adjusted for multiple testing \n",
      "and should not be used to infer definitive effects. ACE denotes angiotensin-converting enzyme, ARB angiotensin-receptor blocker, and \n",
      "COPD chronic obstructive pulmonary disease.\n",
      "˜˚˛˜˛˚˛ˇˇˇ˜˛–•˜˛˜˛ˇ‡˜˛˚ƒ…ˇˇƒ—•˜⁄—ˇ‡˜ˆ˚–…ˇˇ–ˆ•–˛€ˇ‡˜˜˚ˆ…ˇˇ–ƒ•ƒƒˆˇ‡˜€˚ƒ…€˙•€—˜ˇ‡—˚€…–⁄•ˆˆ˙ˇ‡˙˚⁄…–˙•⁄˙˛ˇ‡€˚ƒ…––˙•ˆ––—ˇ‡˙˚–…€⁄˛•⁄˙˛˙ˇ‡ˆ˚˙…€⁄–•⁄˙⁄ˆˇ‡ˆ˚˙…€˙—•⁄€˜—ˇ‡ˆ˚˙…€——•⁄˜€˛ˇ‡˙˚˜…˜˚—–ˇ‡˜˚˙˛‹ƒ˚€˜…ˆ‹˛˚—ˆ…⁄‹–˚ˆ˜…ƒ˚€⁄ˇ‡˜˚˙ƒ‹˜˚—ˆˇ‡˜˚––‹ƒ˚⁄˙…ƒ˚—˙ˇ‡ƒ˚˛˛‹€˚€˛…—‹˛˚––ˇ‡˛˚ƒ˛‹˛˚ˆ€…˜˚ƒ–ˇ‡˛˚⁄˛˚–ˆˇ‡˛˚ƒ€‹˛˚ˆƒ…˛˚˜ n engl j med   \n",
      "nejm.org 7Cardiovascular Disease in Covid-19\n",
      "tion of the tissue reninŒangiotensinŒaldosterone \n",
      "system while mediating the release of proin\n",
      "-flammatory cytokines into the circulation.\n",
      "21 The \n",
      "stress of critical illness and inflammation may \n",
      "unite in destabilizing preexisting cardiovascular \n",
      "illness. Vascular endothelial cell dysfunction, in\n",
      "-flammation-associated myocardial depression, \n",
      "stress cardiomyopathy, direct viral infection of \n",
      "the heart and its vessels, or the host response may \n",
      "cause or worsen heart failure, demand-related isch\n",
      "-emia, and arrhythmias.\n",
      "22 These factors may under\n",
      "-lie the observed associations between cardiovascu\n",
      "-lar disease and death in Covid-19.\n",
      "In our analyses, use of either ACE inhibitors \n",
      "or statins was associated with better survival \n",
      "among patients with Covid-19. However, these as\n",
      "-sociations should be considered with extreme cau\n",
      "-tion. Because our study was not a randomized, \n",
      "controlled trial, we cannot exclude the possibility \n",
      "of confounding. In addition, we examined rela\n",
      "-tionships between many variables and in-hospi\n",
      "-tal death, and no primary hypothesis was pre\n",
      "-specified; these factors increased the probability \n",
      "of chance associations being found. Therefore, a \n",
      "cause-and-effect relationship between drug ther\n",
      "-apy and survival should not be inferred. These \n",
      "data also offer no information concerning the \n",
      "potential effect of initiation of ACE inhibitor or \n",
      "statin therapy in patients with Covid-19 who do \n",
      "not have an appropriate indication for these \n",
      "medications. Randomized clinical trials evaluat\n",
      "-ing the role of ACE inhibitors and statins will be \n",
      "necessary before any conclusion can be reached \n",
      "regarding a potential benefit of these agents in \n",
      "patients with Covid-19.\n",
      "In this multinational observational study in\n",
      "-volving patients hospitalized with Covid-19, we \n",
      "confirmed previous observations suggesting that \n",
      "underlying cardiovascular disease is independently \n",
      "associated with an increased risk of in-hospital \n",
      "death. We were not able to confirm previous con\n",
      "-cerns regarding a potential harmful association \n",
      "of ACE inhibitors or ARBs with in-hospital mor\n",
      "-tality in this clinical context.\n",
      "Supported by the William Harvey Distinguished Chair in \n",
      "Advanced Cardiovascular Medicine at Brigham and Women™s \n",
      "Hospital. The development and maintenance of the Surgical \n",
      "Outcomes Collaborative database was funded by Surgisphere.\n",
      "Disclosure forms provided by the authors are available with \n",
      "the full text of this article at NEJM.org.\n",
      "References\n",
      "1. Ruan Q, Yang K, Wang W, Jiang L, \n",
      "Song J. Clinical predictors of mortality \n",
      "due to COVID-19 based on an analysis of \n",
      "data of 150 patients from Wuhan, China. \n",
      "Intensive Care Med 2020 March 3 (Epub \n",
      "ahead of print).\n",
      "2. Shi S, Qin M, Shen B, et al. Associa\n",
      "-tion of cardiac injury with mortality in \n",
      "hospitalized patients with COVID-19 in \n",
      "Wuhan, China. JAMA Cardiol 2020 March \n",
      "25 (Epub ahead of print).\n",
      "3. Guo T, Fan Y, Chen M, et al. Cardio\n",
      "-vascular implications of fatal outcomes of \n",
      "patients with coronavirus disease 2019 \n",
      "(COVID-19). JAMA Cardiol 2020 March 27 \n",
      "(Epub ahead of print).\n",
      "4. Arentz M, Yim E, Klaff L, et al. Char\n",
      "-acteristics and outcomes of 21 critically ill \n",
      "patients with COVID-19 in Washington \n",
      "State. JAMA 2020 March 19 (Epub ahead \n",
      "of print).\n",
      "5. Nguyen JL, Yang W, Ito K, Matte TD, \n",
      "Shaman J, Kinney PL. Seasonal influenza \n",
      "infections and cardiovascular disease \n",
      "mortality. JAMA Cardiol 2016;\n",
      " \n",
      "1:\n",
      " \n",
      "274-81.\n",
      "6. Fang L, Karakiulakis G, Roth M. Are \n",
      "patients with hypertension and diabetes \n",
      "mellitus at increased risk for COVID-19 \n",
      "infection? Lancet Respir Med 2020;\n",
      " \n",
      "8(4):\n",
      " e21.\n",
      "7. Nicin L, Abplanalp WT, Mellentin H, \n",
      "et al. Cell type-specific expression of the \n",
      "putative SARS-CoV-2 receptor ACE2 in hu\n",
      "-man hearts. Eur Heart J 2020 April 15 \n",
      "(Epub ahead of print).\n",
      "8. Hoffmann M, Kleine-Weber H, Schro\n",
      "-eder S, et al. SARS-CoV-2 cell entry de\n",
      "-pends on ACE2 and TMPRSS2 and is \n",
      "blocked by a clinically proven protease \n",
      "inhibitor. Cell 2020;\n",
      " 181(2):\n",
      " 271.e8-280.e8.\n",
      "9. Rice GI, Thomas DA, Grant PJ, Turner \n",
      "AJ, Hooper NM. Evaluation of angioten\n",
      "-sin-converting enzyme (ACE), its homo\n",
      "-logue ACE2 and neprilysin in angiotensin \n",
      "peptide metabolism. Biochem J 2004;\n",
      " \n",
      "383:\n",
      " 45-51.\n",
      "10.\n",
      " Walls AC, Park YJ, Tortorici MA, Wall \n",
      "A, McGuire AT, Veesler D. Structure, \n",
      "function, and antigenicity of the SARS-\n",
      "CoV-2 spike glycoprotein. Cell 2020;\n",
      " 181(2):\n",
      " 281.e6-292.e6.\n",
      "11.\n",
      " Li XC, Zhang J, Zhuo JL. The vasopro\n",
      "-tective axes of the renin-angiotensin sys\n",
      "-tem: physiological relevance and thera\n",
      "-peutic implications in cardiovascular, \n",
      "hypertensive and kidney diseases. Phar\n",
      "-macol Res 2017;\n",
      " 125:\n",
      " 21-38.\n",
      "12.\n",
      " Ferrario CM, Jessup J, Chappell MC, et \n",
      "al. Effect of angiotensin-converting en\n",
      "-zyme inhibition and angiotensin II recep\n",
      "-tor blockers on cardiac angiotensin-con\n",
      "-verting enzyme 2. Circulation 2005;\n",
      " \n",
      "111:\n",
      " 2605-10.\n",
      "13.\n",
      " Patel AB, Verma A. COVID-19 and \n",
      "angiotensin-converting enzyme inhibi\n",
      "-tors and angiotensin receptor blockers: \n",
      "what is the evidence? JAMA 2020 March \n",
      "24 (Epub ahead of print).\n",
      "14.\n",
      " American College of Cardiology. \n",
      "HFSA/ACC/AHA statement addresses \n",
      "concerns re: using RAAS antagonists in \n",
      "COVID-19. March 17, 2020 (https://www\n",
      " .acc\n",
      " .org/\n",
      " latest\n",
      " - in\n",
      " - cardiology/\n",
      " articles/\n",
      " 2020/\n",
      " 03/\n",
      " 17/\n",
      " 08/\n",
      " 59/\n",
      " hfsa\n",
      " - acc\n",
      " - aha\n",
      " - statement\n",
      " - addresses\n",
      " - concerns\n",
      " - re\n",
      " - using\n",
      " - raas\n",
      " - antagonists\n",
      " - in\n",
      " - covid\n",
      " - 19).\n",
      "15.\n",
      " European Society of Cardiology. Posi\n",
      "-tion statement of the ESC Council on Hy\n",
      "-pertension on ACE-inhibitors and angio\n",
      "-tensin receptor blockers. March 13, 2020 \n",
      "(https://www\n",
      " .escardio\n",
      " .org/\n",
      " Councils/\n",
      " Council\n",
      " - on - Hypertension\n",
      " - (CHT)/\n",
      " News/\n",
      " position\n",
      " - statement\n",
      " - of - the\n",
      " - esc\n",
      " - council\n",
      " - on - hypertension\n",
      " - on - ace\n",
      " - inhibitors\n",
      " - and\n",
      " - ang).\n",
      "16.\n",
      " World Health Organization. Clinical \n",
      "management of severe acute respiratory \n",
      "infection (SARI) when COVID-19 disease \n",
      "is suspected: interim guidance. March 13, \n",
      "2020 (https://www\n",
      " .who\n",
      " .int/\n",
      " docs/\n",
      " default\n",
      " - source/\n",
      " coronaviruse/\n",
      " clinical\n",
      " - management\n",
      " - of\n",
      " - novel\n",
      " - cov\n",
      " .pdf).\n",
      "17.\n",
      " Karlberg J, Chong DSY, Lai WYY. Do \n",
      "men have a higher case fatality rate of se\n",
      "-vere acute respiratory syndrome than \n",
      "women do? Am J Epidemiol 2004;\n",
      " \n",
      "159:\n",
      " \n",
      "229-\n",
      "31.\n",
      " n engl j med   \n",
      "nejm.org 8The\n",
      " new england journal \n",
      "of medicine\n",
      "18.\n",
      " Klein SL, Flanagan KL. Sex differenc\n",
      "-es in immune responses. Nat Rev Immu\n",
      "-nol 2016;\n",
      " 16:\n",
      " 626-38.\n",
      "19.\n",
      " Channappanavar R, Fett C, Mack M, \n",
      "Ten Eyck PP, Meyerholz DK, Perlman S. \n",
      "Sex-based differences in susceptibility to \n",
      "severe acute respiratory syndrome coro\n",
      "-navirus infection. J Immunol 2017;\n",
      " \n",
      "198:\n",
      " 4046-53.\n",
      "20.\n",
      " Siddiqi HK, Mehra MR. COVID-19 ill\n",
      "-ness in native and immunosuppressed \n",
      "states: a clinical-therapeutic staging propos\n",
      "-al. J Heart Lung Transplant 2020;\n",
      " \n",
      "39:\n",
      " \n",
      "405-7.\n",
      "21.\n",
      " Wang K, Gheblawi M, Oudit GY. An\n",
      "-giotensin converting enzyme 2: a double-\n",
      "edged sword. Circulation 2020 March 26 \n",
      "(Epub ahead of print).\n",
      "22.\n",
      " Mehra MR, Ruschitzka F. COVID-19 \n",
      "illness and heart failure: a missing link? \n",
      "JACC Heart Fail (in press).\n",
      "Copyright © 2020 Massachusetts Medical Society.\n",
      "\n"
     ]
    }
   ],
   "source": [
    "print(pdf_text)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "metadata": {},
   "outputs": [],
   "source": [
    "import ftfy\n",
    "text = ftfy.fix_text(pdf_text)\n",
    "text = ftfy.fix_encoding(text)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "n engl j med \n",
      "nejm.org 1From Brigham and Women™s Hospital \n",
      "Heart and Vascular Center and Harvard \n",
      "Medical School, Boston (M.R.M.); Surgi\n",
      "-sphere, Chicago (S.S.D.); Baylor College of \n",
      "Medicine and Department of Veterans Af\n",
      "-fairs, Houston (S.K.); Christ Hospital, Cin\n",
      "-cinnati (T.D.H.); the Department of Bio\n",
      "-medical Engineering, University of Utah, \n",
      "Salt Lake City (A.N.P.); and HCA Research \n",
      "Institute, Nashville (A.N.P.). Address re\n",
      "-print requests to Dr. Mehra at Brigham \n",
      "and Women™s Hospital, 75 Francis St., \n",
      "Boston, MA 02115, or at \n",
      " \n",
      "mmehra@\n",
      " \n",
      "bwh\n",
      " . harvard\n",
      " . edu.\n",
      "This article was published on May 1, 2020, \n",
      "and updated on May 8, 2020, at NEJM.org.\n",
      "DOI:˜10.1056/NEJMoa2007621\n",
      "Copyright © 2020 Massachusetts Medical Society.BACKGROUND\n",
      "Coronavirus disease 2019 (Covid-19) may disproportionately affect people with \n",
      "cardiovascular disease. Concern has been aroused regarding a potential harmful \n",
      "effect of angiotensin-convertingŒenzyme (ACE) inhibitors and angiotensin-recep\n",
      "-tor blockers (ARBs) in this clinical context.\n",
      "METHODS\n",
      "Using an observational database from 169 hospitals in Asia, Europe, and North \n",
      "America, we evaluated the relationship of cardiovascular disease and drug therapy \n",
      "with in-hospital death among hospitalized patients with Covid-19 who were admit\n",
      "-ted between December 20, 2019, and March 15, 2020, and were recorded in the \n",
      "Surgical Outcomes Collaborative registry as having either died in the hospital or \n",
      "survived to discharge as of March 28, 2020.\n",
      "RESULTS\n",
      "Of the 8910 patients with Covid-19 for whom discharge status was available at the \n",
      "time of the analysis, a total of 515 died in the hospital (5.8%) and 8395 survived \n",
      "to discharge. The factors we found to be independently associated with an in\n",
      "-creased risk of in-hospital death were an age greater than 65 years (mortality of \n",
      "10.0%, vs. 4.9% among those ˜65 years of age; odds ratio, 1.93; 95% confidence \n",
      "interval [CI], 1.60 to 2.41), coronary artery disease (10.2%, vs. 5.2% among those \n",
      "without disease; odds ratio, 2.70; 95% CI, 2.08 to 3.51), heart failure (15.3%, vs. \n",
      "5.6% among those without heart failure; odds ratio, 2.48; 95% CI, 1.62 to 3.79), \n",
      "cardiac arrhythmia (11.5%, vs. 5.6% among those without arrhythmia; odds ratio, \n",
      "1.95; 95% CI, 1.33 to 2.86), chronic obstructive pulmonary disease (14.2%, vs. \n",
      "5.6% among those without disease; odds ratio, 2.96; 95% CI, 2.00 to 4.40), and \n",
      "current smoking (9.4%, vs. 5.6% among former smokers or nonsmokers; odds \n",
      "ratio, 1.79; 95% CI, 1.29 to 2.47). No increased risk of in-hospital death was found \n",
      "to be associated with the use of ACE inhibitors (2.1% vs. 6.1%; odds ratio, 0.33; \n",
      "95% CI, 0.20 to 0.54) or the use of ARBs (6.8% vs. 5.7%; odds ratio, 1.23; 95% CI, \n",
      "0.87 to 1.74).\n",
      "CONCLUSIONS\n",
      "Our study confirmed previous observations suggesting that underlying cardiovascu\n",
      "-lar disease is associated with an increased risk of in-hospital death among patients \n",
      "hospitalized with Covid-19. Our results did not confirm previous concerns regarding \n",
      "a potential harmful association of ACE inhibitors or ARBs with in-hospital death in \n",
      "this clinical context. (Funded by the William Harvey Distinguished Chair in Ad\n",
      "-vanced Cardiovascular Medicine at Brigham and Women™s Hospital.)\n",
      "ABSTRACT\n",
      "Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19Mandeep R. Mehra, M.D., Sapan\n",
      " S. Desai, M.D., Ph.D., \n",
      "SreyRam Kuy, M.D., M.H.S., Timothy\n",
      " D. Henry, M.D., and Amit\n",
      " N. Patel, M.D.\n",
      " \n",
      "Original Article\n",
      " n engl j med \n",
      "nejm.org 2The\n",
      " new england journal \n",
      "of medicine\n",
      "As the coronavirus disease 2019 \n",
      "(Covid-19) pandemic has spread around \n",
      "the globe, there has been growing recog\n",
      "-nition that persons with underlying increased \n",
      "cardiovascular risk may be disproportionately \n",
      "affected.\n",
      "1-3\n",
      " Several studies of case series have \n",
      "noted cardiac arrhythmias, cardiomyopathy, and \n",
      "cardiac arrest as terminal events in patients with \n",
      "Covid-19.\n",
      "1-4\n",
      " Higher incidences of cardiac arrhyth\n",
      "-mias, acute coronary syndromes, and heart fail\n",
      "-ureŒrelated events have also been reported during \n",
      "seasonal influenza outbreaks, which suggests that \n",
      "acute respiratory infections may result in activa\n",
      "-tion of coagulation pathways, proinflammatory \n",
      "effects, and endothelial cell dysfunction.\n",
      "5 In ad\n",
      "-dition, however, concern has been expressed that \n",
      "medical therapy for cardiovascular disease might \n",
      "specifically contribute to the severity of illness \n",
      "in patients with Covid-19.\n",
      "6,7\n",
      "Severe acute respiratory syndrome coronavirus \n",
      "2 (SARS-CoV-2), the causative agent of Covid-19, \n",
      "has been shown to establish itself in the host \n",
      "through the use of angiotensin-converting en\n",
      "-zyme 2 (ACE2) as its cellular receptor.\n",
      "8 ACE2 is \n",
      "a membrane-bound monocarboxypeptidase found \n",
      "ubiquitously in humans and expressed predomi\n",
      "-nantly in heart, intestine, kidney, and pulmonary \n",
      "alveolar (type II) cells.\n",
      "7,9\n",
      " Entry of SARS-CoV-2 \n",
      "into human cells is facilitated by the interaction \n",
      "of a receptor-binding domain in its viral spike \n",
      "glycoprotein ectodomain with the ACE2 receptor.\n",
      "10ACE2 is counterregulatory to the activity of \n",
      "angiotensin II generated through ACE1 and is \n",
      "protective against detrimental activation of the \n",
      "reninŒangiotensinŒaldosterone system. Angioten\n",
      "-sin II is catalyzed by ACE2 to angiotensin-(1Œ7), \n",
      "which exerts vasodilatory, antiinflammatory, an\n",
      "-tifibrotic, and antigrowth effects.\n",
      "11 It has been \n",
      "suggested that ACE inhibitors and angiotensin-\n",
      "receptor blockers (ARBs) may increase the expres\n",
      "-sion of ACE2, which has been shown in the heart \n",
      "in rats,\n",
      "12 and thereby may confer a predisposition \n",
      "to more severe infection and adverse outcomes \n",
      "during Covid-19.\n",
      "6,7\n",
      " Others have suggested that \n",
      "ACE inhibitors may counter the antiinflammatory \n",
      "effects of ACE2. However, in vitro studies have \n",
      "not shown direct inhibitory activity of ACE in\n",
      "-hibitors against ACE2 function.\n",
      "9,13\n",
      "Despite these uncertainties, some have rec\n",
      "-ommended cessation of treatment with ACE in\n",
      "-hibitors and ARBs in patients with Covid-19.\n",
      "6 However, several scientific societies, including \n",
      "the American Heart Association, the American \n",
      "College of Cardiology, the Heart Failure Society \n",
      "of America, and the Council on Hypertension of \n",
      "the European Society of Cardiology, have urged \n",
      "that these important medications should not be \n",
      "discontinued in the absence of clear clinical evi\n",
      "-dence of harm.\n",
      "14,15\n",
      " We therefore undertook a study \n",
      "to investigate the relationship between underlying \n",
      "cardiovascular disease and Covid-19 outcomes and \n",
      "to evaluate the association between cardiovascular \n",
      "drug therapy and mortality in this illness.\n",
      "Methods\n",
      "Data Source\n",
      "We analyzed deidentified data from the Surgical \n",
      "Outcomes Collaborative (Surgisphere), an interna\n",
      "-tional registry. Our analysis included data from \n",
      "169 hospitals located in 11 countries in Asia, \n",
      "Europe, and North America. The collaborative uses \n",
      "automated extraction of data from inpatient and \n",
      "outpatient electronic health records, supply-chain \n",
      "databases, and financial records, combined with \n",
      "point-of-care data entry for procedures. A manual \n",
      "data-entry process is used for quality assurance \n",
      "and validation. Data are collected through auto\n",
      "-mated data transfers that capture information \n",
      "from each health care entity at regular intervals \n",
      "on a prospective, ongoing basis. Verifiable source \n",
      "documentation for the data elements includes elec\n",
      "-tronic inpatient and outpatient medical records.\n",
      "Data acquisition is facilitated through the use \n",
      "of a standardized Health Level SevenŒcompliant \n",
      "data dictionary. After this data dictionary is har\n",
      "-monized with data from electronic health records, \n",
      "the majority of the data acquisition is completed \n",
      "with automated interfaces. The collected data \n",
      "sample from each health care entity is validated \n",
      "against financial records and external databas\n",
      "-es. All protected health information is stripped \n",
      "from each record before storage in a cloud-based \n",
      "data warehouse. The collaborative is compliant \n",
      "with the Agency for Healthcare Research and \n",
      "Quality guidelines for registries and the Food and \n",
      "Drug Administration guidance on real-world evi\n",
      "-dence. The collection and analysis of data in the \n",
      "registry have been deemed exempt from ethics \n",
      "review.\n",
      "Data Collection\n",
      "The collaborative registry was used as a resource \n",
      "to analyze data from all patients with polymerase-\n",
      " n engl j med \n",
      "nejm.org 3Cardiovascular Disease in Covid-19\n",
      "chain-reaction (PCR)Œproven Covid-19 who were \n",
      "admitted to the hospital between December 20, \n",
      "2019, and March 15, 2020, and who were re\n",
      "-corded in the registry as having either died in \n",
      "the hospital or survived to hospital discharge as \n",
      "of March 28, 2020. Data from the registry can be \n",
      "analyzed only after a patient™s hospitalization is \n",
      "complete, and therefore our sample did not in\n",
      "-clude patients who were admitted to the hospital \n",
      "during this time window but were still hospital\n",
      "-ized at the end of it. Our sample also may have \n",
      "excluded some patients who had died or were \n",
      "discharged by March 28 but whose discharge \n",
      "status had not yet been recorded by the hospital.\n",
      "The presence in the record of a positive labo\n",
      "-ratory finding confirming SARS-CoV-2 infection \n",
      "was used for classifying a patient as positive for \n",
      "Covid-19. A positive laboratory finding for SARS-\n",
      "CoV-2 was defined as a positive result on high-\n",
      "throughput sequencing or real-time reverse-tran\n",
      "-scriptaseŒPCR (RT-PCR) assay of nasal or \n",
      "pharyngeal swab specimens. At each site, Covid-19 \n",
      "was diagnosed on the basis of the World Health \n",
      "Organization guidance.\n",
      "16 Patients who did not \n",
      "undergo testing, had no record of testing in the \n",
      "collaborative database, or had a negative test \n",
      "were not included in the present study. For this \n",
      "study, only one positive test was necessary for \n",
      "the patient to be included in the analysis.\n",
      "Data on patients™ demographic characteris\n",
      "-tics, coexisting conditions (based on codes from \n",
      "the \n",
      "International Classification of Diseases, 10th Revi\n",
      "-sion, Clinical Modification\n",
      "), and cardiovascular drug \n",
      "therapy were included in this analysis. Clinical \n",
      "information included age, sex, continent of ori\n",
      "-gin, and underlying coexisting conditions as \n",
      "noted in either the inpatient or the outpatient \n",
      "electronic health record. Coexisting conditions \n",
      "included chronic obstructive pulmonary disease \n",
      "(COPD), an immunosuppressed condition (glu\n",
      "-cocorticoid use, a preexisting immunologic con\n",
      "-dition, or ongoing chemotherapy in patients \n",
      "with cancer), current or remote history of smok\n",
      "-ing, and a history of hypertension, diabetes mel\n",
      "-litus, hyperlipidemia, or underlying cardiovascu\n",
      "-lar disease (including coronary artery disease, \n",
      "heart failure, and cardiac arrhythmia). Cardio\n",
      "-vascular drug therapy recorded at the time of \n",
      "hospital admission was also included, including \n",
      "any antiplatelet therapy, use of insulin or other \n",
      "hypoglycemic agents, beta-blockers, statins, ARBs, \n",
      "and ACE inhibitors.\n",
      "All the authors reviewed the manuscript and \n",
      "vouch for the accuracy and completeness of the \n",
      "data provided.\n",
      "Statistical Analysis\n",
      "The primary analysis was an evaluation of the \n",
      "relationship of preexisting cardiovascular dis\n",
      "-ease and drug therapy with the end point of in-\n",
      "hospital death while controlling for confound\n",
      "-ers, including demographic characteristics and \n",
      "coexisting conditions. Categorical variables are \n",
      "shown as frequencies and percentages, and con\n",
      "-tinuous variables as means and standard devia\n",
      "-tions. Independent sample t-tests were complet\n",
      "-ed, and point differences with 95% confidence \n",
      "intervals are reported for all comparisons be\n",
      "-tween variables. Multiple imputation for missing \n",
      "values was not possible because for disease and \n",
      "drug variables there were no codes to indicate \n",
      "that data were missing; if the patient™s elec\n",
      "-tronic health record did not include information \n",
      "on a clinical characteristic, such as hyperlipid\n",
      "-emia or the use of beta-blockers, it was assumed \n",
      "that that characteristic was not present.\n",
      "A multivariable logistic-regression analysis \n",
      "was performed to ascertain the effects of age, \n",
      "race, coexisting conditions (coronary artery dis\n",
      "-ease, congestive heart failure, cardiac arrhyth\n",
      "-mia, diabetes mellitus, COPD, current smoking, \n",
      "former smoking, hypertension, immunocompro\n",
      "-mised state, and hyperlipidemia), hospital loca\n",
      "-tion (according to country), and medications \n",
      "(ACE inhibitors, ARBs, beta-blockers, antiplate\n",
      "-let agents, statins, insulin, and oral hypoglyce\n",
      "-mic agents) on the likelihood of in-hospital \n",
      "death. Linearity of the continuous variables with \n",
      "respect to the logit of the dependent variable was \n",
      "confirmed. Odds ratios and corresponding 95% \n",
      "confidence intervals were calculated. Separate \n",
      "age- and sex-adjusted analyses were also per\n",
      "-formed. The 95% confidence intervals have not \n",
      "been adjusted for multiple testing and should \n",
      "not be used to infer definitive effects.\n",
      "On the basis of the results of the initial \n",
      "analyses, additional analyses were performed to \n",
      "examine the robustness of the estimates initially \n",
      "obtained. Analyses according to continent of ori\n",
      "-gin as well as country classification (as either high \n",
      "income or lowŒmiddle income) were performed. \n",
      "A tipping-point analysis (an analysis that shows \n",
      "the effect size and prevalence of an unmeasured \n",
      "confounder that could shift the upper boundary \n",
      " n engl j med \n",
      "nejm.org 4The\n",
      " new england journal \n",
      "of medicine\n",
      "of the confidence interval toward null) was per\n",
      "-formed. In addition, we sought to determine \n",
      "whether the effect of ACE inhibitors and statins \n",
      "noted in the overall study was also seen when \n",
      "the analysis was confined to a subgroup of pa\n",
      "-tients who might have an indication for these \n",
      "agents. Thus, the association of ACE inhibitor \n",
      "use with in-hospital death was examined in the \n",
      "subgroup of patients with hypertension, and the \n",
      "association of statin use with in-hospital death \n",
      "was examined in the subgroup of patients with \n",
      "hyperlipidemia, with the use of age- and sex-\n",
      "adjusted logistic-regression analysis. All statistical \n",
      "analyses were performed with R software, version \n",
      "3.6.3 (R Foundation for Statistical Computing), \n",
      "and SPSS Statistics software, version 26 (IBM).\n",
      "Results\n",
      "Patients\n",
      "Our study population included 8910 hospitalized \n",
      "patients from 169 hospitals who had Covid-19, \n",
      "who were admitted between December 20, 2019, \n",
      "and March 15, 2020, and who completed their \n",
      "hospital course (discharged alive or died) by March \n",
      "28, 2020. Patients who were hospitalized during \n",
      "this time without a completed course could not \n",
      "be included in the analysis. Our sample was \n",
      "made up of 1536 patients (17.2%) from North \n",
      "America, 5755 (64.6%) from Europe, and 1619 \n",
      "(18.2%) from Asia (details of the study popula\n",
      "-tion according to continent, country, and num\n",
      "-ber of hospitals are provided in Table S1 in the \n",
      "Supplementary Appendix, available with the full \n",
      "text of this article at NEJM.org). The mean (±SD) \n",
      "age was 49±16 years (16.5% of the patients were \n",
      ">65 years of age), 40.0% of the patients were \n",
      "women, 63.5% were white, 7.9% were black, 6.3% \n",
      "were Hispanic, and 19.3% were Asian.\n",
      "With respect to cardiovascular risk factors, \n",
      "30.5% of the patients had hyperlipidemia, 26.3% \n",
      "had hypertension, 14.3% had diabetes mellitus, \n",
      "16.8% were former smokers, and 5.5% were cur\n",
      "-rent smokers. Preexisting cardiovascular disease \n",
      "in this sample included coronary artery disease \n",
      "(present in 11.3% of the patients), a history of con\n",
      "-gestive heart failure (2.1%), and a history of cardiac \n",
      "arrhythmia (3.4%). Other coexisting conditions \n",
      "included COPD (in 2.5% of the patients) and an \n",
      "underlying immunosuppressed condition (2.8%). \n",
      "Medical therapy included ACE inhibitors (8.6% \n",
      "of the patients), ARBs (6.2%), statins (9.7%), \n",
      "beta-blockers (5.9%), and antiplatelet agents (3.3%). \n",
      "Insulin was used in 3.4% of the patients, and \n",
      "other hypoglycemic agents were used in 9.6%. \n",
      "The mean length of hospital stay was 10.7±2.7 \n",
      "days, with an overall in-hospital mortality of \n",
      "5.8% (515 of 8910 patients) in this population of \n",
      "patients with completed outcomes. Of the pa\n",
      "-tients who had been admitted to an intensive care \n",
      "unit (ICU) at any time during their hospitaliza\n",
      "-tion, 24.7% died, as compared with 4.0% of the \n",
      "patients who had not been admitted to an ICU.\n",
      "Analysis of Survivors as Compared \n",
      " with Nonsurvivors\n",
      "Table\n",
      " 1 shows the distribution of demographic \n",
      "characteristics and coexisting conditions among \n",
      "survivors and nonsurvivors, along with the be\n",
      "-tween-group differences and 95% confidence in\n",
      "-tervals. Nonsurvivors were older, more likely to be \n",
      "white, and more often men, and they had a \n",
      "greater prevalence of diabetes mellitus, hyperlip\n",
      "-idemia, coronary artery disease, heart failure, \n",
      "and cardiac arrhythmias. Patients who died were \n",
      "also more likely to have had COPD and a history \n",
      "of current smoking. Among medications, ACE in\n",
      "-hibitors and statins were more commonly used by \n",
      "survivors than by nonsurvivors (Table\n",
      " 2), whereas \n",
      "no association between survival and the use of \n",
      "ARBs was found. The length of hospital stay dif\n",
      "-fered between survivors and nonsurvivors (10.5±2.5 \n",
      "days vs. 7.5±2.8 days). When the data were ana\n",
      "-lyzed according to age decile, continent, or in\n",
      "-come category of the country in which the hos\n",
      "-pital was located (high income or lowŒmiddle \n",
      "income), the results were similar (Fig. S1 and \n",
      "Tables S2 and S3).\n",
      "Multivariable Logistic-Regression Analysis\n",
      "A multivariable logistic-regression model was \n",
      "developed. Independent predictors of in-hospital \n",
      "death and their corresponding odds ratios and \n",
      "95% confidence intervals are shown in Figure\n",
      " 1. \n",
      "An age greater than 65 years, coronary artery \n",
      "disease, congestive heart failure, cardiac arrhyth\n",
      "-mia, COPD, and current smoking were associat\n",
      "-ed with a higher risk of in-hospital death. Fe\n",
      "-male sex, the use of ACE inhibitors, and the use \n",
      "of statins were associated with a better chance \n",
      "of survival to hospital discharge, with no associa\n",
      "-tion found for the use of ARBs. For female sex, \n",
      " n engl j med \n",
      "nejm.org 5Cardiovascular Disease in Covid-19\n",
      "the odds ratio for dying in the hospital was 0.79 \n",
      "(95% confidence interval [CI], 0.65 to 0.95); for \n",
      "ACE inhibitor use, the odds ratio was 0.33 (95% \n",
      "CI, 0.20 to 0.54); and for statin use, the odds \n",
      "ratio was 0.35 (95% CI, 0.24 to 0.52). For ARB \n",
      "use, the odds ratio was 1.23 (95% CI, 0.87 to \n",
      "1.74). The presence or absence of an immuno\n",
      "-suppressed condition, the race or ethnic group, \n",
      "and the presence or absence of hyperlipidemia \n",
      "or diabetes mellitus were not independent pre\n",
      "-dictors of death in the hospital. The analyses \n",
      "according to continent and according to the in\n",
      "-come category of the country (high or lowŒmiddle) \n",
      "were consistent with the overall results (Tables \n",
      "S4 and S5). Data from the age- and sex-adjusted \n",
      "multivariable logistic-regression analyses are \n",
      "shown in Table S6.\n",
      "Table˜1.\n",
      "˜Demographic˜Characteristics˜and˜Coexisting˜Conditions˜among˜Survivors˜and˜Nonsurvivors˜of˜Covid-19.*\n",
      "Characteristic˜or˜Condition\n",
      "Survivors˜(N˜=˜8395)Nonsurvivors˜(N˜=˜515)Difference˜(95%˜CI)ƒ\n",
      "Age Š yr\n",
      "48.7±16.655.8±15.1˜7.1 (˜8.4 to ˜5.7)\n",
      "Age >65 yr Š no. (%)\n",
      "1327 (15.8)\n",
      "147 (28.5)\n",
      "˜12.7 (˜16.0 to ˜9.4)\n",
      "Female sex Š no. (%)\n",
      "3392 (40.4)\n",
      "179 (34.8)\n",
      "5.6 (1.3 to 10.0)\n",
      "Race or ethnic group Š no. (%)⁄\n",
      "White5306 (63.2)\n",
      "351 (68.2)\n",
      "˜5.0 (˜9.1 to ˜0.8)\n",
      "Black672 (8.0)\n",
      "34 (6.6)\n",
      "1.4 (˜0.8 to 3.6)\n",
      "Hispanic529 (6.3)\n",
      "32 (6.2)\n",
      "0.1 (˜2.0 to 2.3)\n",
      "Asian1637 (19.5)\n",
      "84 (16.3)\n",
      "3.2 (˜0.2 to 6.5)\n",
      "Native American\n",
      "34 (0.4)\n",
      "1 (0.2)\n",
      "0.2 (˜0.3 to 0.8)\n",
      "Other219 (2.6)\n",
      "13 (2.5)\n",
      "0.1 (˜1.4 to 1.4)\n",
      "Coexisting conditions Š no. (%)\n",
      "Coronary artery disease\n",
      "907 (10.8)\n",
      "103 (20.0)\n",
      "˜9.2 (˜12.8 to ˜5.7)\n",
      "Congestive heart failure\n",
      "160 (1.9)\n",
      "29 (5.6)\n",
      "˜3.7 (˜5.8 to ˜1.8)\n",
      "Cardiac arrhythmia269 (3.2)\n",
      "35 (6.8)\n",
      "˜3.6 (˜5.8 to ˜1.4)\n",
      "Diabetes mellitus\n",
      "1175 (14.0)\n",
      "97 (18.8)\n",
      "˜4.8 (˜8.3 to ˜1.3)\n",
      "Hypertension2216 (26.4)\n",
      "130 (25.2)\n",
      "1.2 (˜2.8 to 5.1)\n",
      "Hyperlipidemia2535 (30.2)\n",
      "180 (35.0)\n",
      "˜4.8 (˜9.0 to ˜0.5)\n",
      "COPD193 (2.3)\n",
      "32 (6.2)\n",
      "˜3.9 (˜6.1 to ˜1.8)\n",
      "Current smoker\n",
      "445 (5.3)\n",
      "46 (8.9)\n",
      "˜3.6 (˜6.2 to ˜1.1)\n",
      "Former smoker\n",
      "1410 (16.8)\n",
      "83 (16.1)\n",
      "0.7 (˜2.6 to 4.0)\n",
      "Immunosuppressed condition\n",
      "227 (2.7)\n",
      "22 (4.3)\n",
      "˜1.6 (˜3.4 to 0.2)\n",
      "* \n",
      "PlusŒminus values are means ±SD. The 95% confidence intervals (CIs) have not been adjusted for multiple testing and should not be used to infer definitive effects. COPD denotes chronic obstructive pulmonary disease, and Covid-19 coro-navirus disease 2019.ƒ \n",
      "For mean age, the difference is given in years; for all other characteristics, the difference is given in percentage points.⁄ \n",
      "Race and ethnic group were reported by the patient.Table˜2.\n",
      "˜Cardiovascular˜Drug˜Therapy˜at˜Hospitalization˜among˜Survivors˜\n",
      "˜and˜Nonsurvivors˜of˜Covid-19.*\n",
      "Drug˜Class\n",
      "Survivors˜(N˜=˜8395)Nonsurvivors˜(N˜=˜515)Difference˜(95%˜CI)\n",
      "number (percent)\n",
      "percentage points\n",
      "ACE inhibitor\n",
      "754 (9.0)\n",
      "16 (3.1)\n",
      "5.9 (4.3 to 7.5)\n",
      "ARB518 (6.2)\n",
      "38 (7.4)\n",
      "˜1.2 (˜3.5 to 1.1)\n",
      "Beta-blocker497 (5.9)\n",
      "28 (5.4)\n",
      "0.5 (˜1.6 to 2.6)\n",
      "Antiplatelet282 (3.4)\n",
      "13 (2.5)\n",
      "0.8 (˜0.6 to 2.2)\n",
      "Statin824 (9.8)\n",
      "36 (7.0)\n",
      "2.8 (0.5 to 5.1)\n",
      "Insulin279 (3.3)\n",
      "23 (4.5)\n",
      "˜1.2 (˜3.0 to 0.7)\n",
      "Other hypoglycemic agent792 (9.4)\n",
      "59 (11.5)\n",
      "˜2.1 (˜4.9 to 0.8)\n",
      "* \n",
      "The 95% confidence intervals have not been adjusted for multiple testing and should not be used to infer definitive effects. ACE denotes angiotensin-converting enzyme, and ARB angiotensin-receptor blocker. n engl j med \n",
      "nejm.org 6The\n",
      " new england journal \n",
      "of medicine\n",
      "Additional Analyses\n",
      "In the tipping-point analysis to assess the poten\n",
      "-tial effect of an unmeasured confounder, it was \n",
      "estimated that a hypothetical unobserved binary \n",
      "confounder with a prevalence of 10% in the study \n",
      "population would need to have an odds ratio of \n",
      "at least 10 in order for the observed associations \n",
      "for either ACE inhibitors or statins to have 95% \n",
      "confidence intervals crossing the odds ratio \n",
      "boundary of 1.0 (Table S7). We also separately \n",
      "examined the interaction of ACE inhibitor use \n",
      "with mortality in the subgroup with hyperten\n",
      "-sion and the interaction of statin use with mor\n",
      "-tality in the subgroup with hyperlipidemia. These \n",
      "analyses, shown in Table S8, are consistent with \n",
      "the results of the primary analysis.\n",
      "Discussion\n",
      "Our investigation confirms previous reports of \n",
      "the independent relationship of older age, under\n",
      "-lying cardiovascular disease (coronary artery dis\n",
      "-ease, heart failure, and cardiac arrhythmias), cur\n",
      "-rent smoking, and COPD with death in Covid-19. \n",
      "Our results also suggest that women are propor\n",
      "-tionately more likely than men to survive the \n",
      "infection. Neither harmful nor beneficial asso\n",
      "-ciations were noted for antiplatelet therapy, beta-\n",
      "blockers, or hypoglycemic therapy. It is important \n",
      "to note that we were not able to confirm previous \n",
      "concerns regarding a potential harmful associa\n",
      "-tion of either ACE inhibitors or ARBs with in-\n",
      "hospital mortality in this clinical context.\n",
      "In viral infections such as influenza, older \n",
      "age is associated with an increased risk of car\n",
      "-diovascular events and death.\n",
      "5 In the 2003 epi\n",
      "-demic of severe acute respiratory syndrome \n",
      "(SARS, caused by SARS-CoV-1 infection), sex \n",
      "differences in the risk of death similar to those \n",
      "we observed were noted.\n",
      "17 Women have stronger \n",
      "innate and adaptive immunity and greater resis\n",
      "-tance to viral infections than men.\n",
      "18 In animal \n",
      "models of SARS-CoV-1 infection, higher suscep\n",
      "-tibility of male mice to SARS-CoV-1 and greater \n",
      "accumulation of macrophages and neutrophils \n",
      "in the lungs have been described.\n",
      "19 Ovariectomy \n",
      "or the use of estrogen-receptor antagonists \n",
      "increased mortality from SARS-CoV-1 infection \n",
      "in female animals. Furthermore, the difference in \n",
      "risk between the sexes increased with advancing \n",
      "age.\n",
      "19 These findings may support the observa\n",
      "-tion in our investigation that suggested an as\n",
      "-sociation between survival and female sex, inde\n",
      "-pendent of older age.\n",
      "Infection with SARS-CoV-2 is a mild disease \n",
      "in most people, but in some the disease pro\n",
      "-gresses to a severe respiratory illness character\n",
      "-ized by a hyperinflammatory syndrome, multi\n",
      "-organ dysfunction, and death.\n",
      "20 In the lung, the \n",
      "viral spike glycoprotein of SARS-CoV-2 interacts \n",
      "with cell-surface ACE2, and the virus is internal\n",
      "-ized by endocytosis. The endocytic event up-\n",
      "regulates the activity of ADAM metallopeptidase \n",
      "domain 17 (ADAM17), which cleaves ACE2 from \n",
      "the cell membrane, resulting in a loss of ACE2-\n",
      "mediated protection against the effects of activa\n",
      "-Figure˜1.\n",
      "˜Independent˜Predictors˜of˜In-Hospital˜Death˜from˜Multivariable˜Logistic-Regression˜Analysis.\n",
      "Numbers and percentages of patients with each risk factor who died (risk factor present) and of patients without each risk factor who \n",
      "died (risk factor absent) are shown. The 95% confidence intervals (CIs) of the odds ratios have not been adjusted for multiple testing \n",
      "and should not be used to infer definitive effects. ACE denotes angiotensin-converting enzyme, ARB angiotensin-receptor blocker, and \n",
      "COPD chronic obstructive pulmonary disease.\n",
      "˜˚˛˜˛˚˛ˇˇˇ˜˛–•˜˛˜˛ˇ‡˜˛˚ƒ…ˇˇƒ—•˜⁄—ˇ‡˜ˆ˚–…ˇˇ–ˆ•–˛€ˇ‡˜˜˚ˆ…ˇˇ–ƒ•ƒƒˆˇ‡˜€˚ƒ…€˙•€—˜ˇ‡—˚€…–⁄•ˆˆ˙ˇ‡˙˚⁄…–˙•⁄˙˛ˇ‡€˚ƒ…––˙•ˆ––—ˇ‡˙˚–…€⁄˛•⁄˙˛˙ˇ‡ˆ˚˙…€⁄–•⁄˙⁄ˆˇ‡ˆ˚˙…€˙—•⁄€˜—ˇ‡ˆ˚˙…€——•⁄˜€˛ˇ‡˙˚˜…˜˚—–ˇ‡˜˚˙˛‹ƒ˚€˜…ˆ‹˛˚—ˆ…⁄‹–˚ˆ˜…ƒ˚€⁄ˇ‡˜˚˙ƒ‹˜˚—ˆˇ‡˜˚––‹ƒ˚⁄˙…ƒ˚—˙ˇ‡ƒ˚˛˛‹€˚€˛…—‹˛˚––ˇ‡˛˚ƒ˛‹˛˚ˆ€…˜˚ƒ–ˇ‡˛˚⁄˛˚–ˆˇ‡˛˚ƒ€‹˛˚ˆƒ…˛˚˜ n engl j med \n",
      "nejm.org 7Cardiovascular Disease in Covid-19\n",
      "tion of the tissue reninŒangiotensinŒaldosterone \n",
      "system while mediating the release of proin\n",
      "-flammatory cytokines into the circulation.\n",
      "21 The \n",
      "stress of critical illness and inflammation may \n",
      "unite in destabilizing preexisting cardiovascular \n",
      "illness. Vascular endothelial cell dysfunction, in\n",
      "-flammation-associated myocardial depression, \n",
      "stress cardiomyopathy, direct viral infection of \n",
      "the heart and its vessels, or the host response may \n",
      "cause or worsen heart failure, demand-related isch\n",
      "-emia, and arrhythmias.\n",
      "22 These factors may under\n",
      "-lie the observed associations between cardiovascu\n",
      "-lar disease and death in Covid-19.\n",
      "In our analyses, use of either ACE inhibitors \n",
      "or statins was associated with better survival \n",
      "among patients with Covid-19. However, these as\n",
      "-sociations should be considered with extreme cau\n",
      "-tion. Because our study was not a randomized, \n",
      "controlled trial, we cannot exclude the possibility \n",
      "of confounding. In addition, we examined rela\n",
      "-tionships between many variables and in-hospi\n",
      "-tal death, and no primary hypothesis was pre\n",
      "-specified; these factors increased the probability \n",
      "of chance associations being found. Therefore, a \n",
      "cause-and-effect relationship between drug ther\n",
      "-apy and survival should not be inferred. These \n",
      "data also offer no information concerning the \n",
      "potential effect of initiation of ACE inhibitor or \n",
      "statin therapy in patients with Covid-19 who do \n",
      "not have an appropriate indication for these \n",
      "medications. Randomized clinical trials evaluat\n",
      "-ing the role of ACE inhibitors and statins will be \n",
      "necessary before any conclusion can be reached \n",
      "regarding a potential benefit of these agents in \n",
      "patients with Covid-19.\n",
      "In this multinational observational study in\n",
      "-volving patients hospitalized with Covid-19, we \n",
      "confirmed previous observations suggesting that \n",
      "underlying cardiovascular disease is independently \n",
      "associated with an increased risk of in-hospital \n",
      "death. We were not able to confirm previous con\n",
      "-cerns regarding a potential harmful association \n",
      "of ACE inhibitors or ARBs with in-hospital mor\n",
      "-tality in this clinical context.\n",
      "Supported by the William Harvey Distinguished Chair in \n",
      "Advanced Cardiovascular Medicine at Brigham and Women™s \n",
      "Hospital. The development and maintenance of the Surgical \n",
      "Outcomes Collaborative database was funded by Surgisphere.\n",
      "Disclosure forms provided by the authors are available with \n",
      "the full text of this article at NEJM.org.\n",
      "References\n",
      "1. Ruan Q, Yang K, Wang W, Jiang L, \n",
      "Song J. Clinical predictors of mortality \n",
      "due to COVID-19 based on an analysis of \n",
      "data of 150 patients from Wuhan, China. \n",
      "Intensive Care Med 2020 March 3 (Epub \n",
      "ahead of print).\n",
      "2. Shi S, Qin M, Shen B, et al. Associa\n",
      "-tion of cardiac injury with mortality in \n",
      "hospitalized patients with COVID-19 in \n",
      "Wuhan, China. JAMA Cardiol 2020 March \n",
      "25 (Epub ahead of print).\n",
      "3. Guo T, Fan Y, Chen M, et al. Cardio\n",
      "-vascular implications of fatal outcomes of \n",
      "patients with coronavirus disease 2019 \n",
      "(COVID-19). JAMA Cardiol 2020 March 27 \n",
      "(Epub ahead of print).\n",
      "4. Arentz M, Yim E, Klaff L, et al. Char\n",
      "-acteristics and outcomes of 21 critically ill \n",
      "patients with COVID-19 in Washington \n",
      "State. JAMA 2020 March 19 (Epub ahead \n",
      "of print).\n",
      "5. Nguyen JL, Yang W, Ito K, Matte TD, \n",
      "Shaman J, Kinney PL. Seasonal influenza \n",
      "infections and cardiovascular disease \n",
      "mortality. JAMA Cardiol 2016;\n",
      " \n",
      "1:\n",
      " \n",
      "274-81.\n",
      "6. Fang L, Karakiulakis G, Roth M. Are \n",
      "patients with hypertension and diabetes \n",
      "mellitus at increased risk for COVID-19 \n",
      "infection? Lancet Respir Med 2020;\n",
      " \n",
      "8(4):\n",
      " e21.\n",
      "7. Nicin L, Abplanalp WT, Mellentin H, \n",
      "et al. Cell type-specific expression of the \n",
      "putative SARS-CoV-2 receptor ACE2 in hu\n",
      "-man hearts. Eur Heart J 2020 April 15 \n",
      "(Epub ahead of print).\n",
      "8. Hoffmann M, Kleine-Weber H, Schro\n",
      "-eder S, et al. SARS-CoV-2 cell entry de\n",
      "-pends on ACE2 and TMPRSS2 and is \n",
      "blocked by a clinically proven protease \n",
      "inhibitor. Cell 2020;\n",
      " 181(2):\n",
      " 271.e8-280.e8.\n",
      "9. Rice GI, Thomas DA, Grant PJ, Turner \n",
      "AJ, Hooper NM. Evaluation of angioten\n",
      "-sin-converting enzyme (ACE), its homo\n",
      "-logue ACE2 and neprilysin in angiotensin \n",
      "peptide metabolism. Biochem J 2004;\n",
      " \n",
      "383:\n",
      " 45-51.\n",
      "10.\n",
      " Walls AC, Park YJ, Tortorici MA, Wall \n",
      "A, McGuire AT, Veesler D. Structure, \n",
      "function, and antigenicity of the SARS-\n",
      "CoV-2 spike glycoprotein. Cell 2020;\n",
      " 181(2):\n",
      " 281.e6-292.e6.\n",
      "11.\n",
      " Li XC, Zhang J, Zhuo JL. The vasopro\n",
      "-tective axes of the renin-angiotensin sys\n",
      "-tem: physiological relevance and thera\n",
      "-peutic implications in cardiovascular, \n",
      "hypertensive and kidney diseases. Phar\n",
      "-macol Res 2017;\n",
      " 125:\n",
      " 21-38.\n",
      "12.\n",
      " Ferrario CM, Jessup J, Chappell MC, et \n",
      "al. Effect of angiotensin-converting en\n",
      "-zyme inhibition and angiotensin II recep\n",
      "-tor blockers on cardiac angiotensin-con\n",
      "-verting enzyme 2. Circulation 2005;\n",
      " \n",
      "111:\n",
      " 2605-10.\n",
      "13.\n",
      " Patel AB, Verma A. COVID-19 and \n",
      "angiotensin-converting enzyme inhibi\n",
      "-tors and angiotensin receptor blockers: \n",
      "what is the evidence? JAMA 2020 March \n",
      "24 (Epub ahead of print).\n",
      "14.\n",
      " American College of Cardiology. \n",
      "HFSA/ACC/AHA statement addresses \n",
      "concerns re: using RAAS antagonists in \n",
      "COVID-19. March 17, 2020 (https://www\n",
      " .acc\n",
      " .org/\n",
      " latest\n",
      " - in\n",
      " - cardiology/\n",
      " articles/\n",
      " 2020/\n",
      " 03/\n",
      " 17/\n",
      " 08/\n",
      " 59/\n",
      " hfsa\n",
      " - acc\n",
      " - aha\n",
      " - statement\n",
      " - addresses\n",
      " - concerns\n",
      " - re\n",
      " - using\n",
      " - raas\n",
      " - antagonists\n",
      " - in\n",
      " - covid\n",
      " - 19).\n",
      "15.\n",
      " European Society of Cardiology. Posi\n",
      "-tion statement of the ESC Council on Hy\n",
      "-pertension on ACE-inhibitors and angio\n",
      "-tensin receptor blockers. March 13, 2020 \n",
      "(https://www\n",
      " .escardio\n",
      " .org/\n",
      " Councils/\n",
      " Council\n",
      " - on - Hypertension\n",
      " - (CHT)/\n",
      " News/\n",
      " position\n",
      " - statement\n",
      " - of - the\n",
      " - esc\n",
      " - council\n",
      " - on - hypertension\n",
      " - on - ace\n",
      " - inhibitors\n",
      " - and\n",
      " - ang).\n",
      "16.\n",
      " World Health Organization. Clinical \n",
      "management of severe acute respiratory \n",
      "infection (SARI) when COVID-19 disease \n",
      "is suspected: interim guidance. March 13, \n",
      "2020 (https://www\n",
      " .who\n",
      " .int/\n",
      " docs/\n",
      " default\n",
      " - source/\n",
      " coronaviruse/\n",
      " clinical\n",
      " - management\n",
      " - of\n",
      " - novel\n",
      " - cov\n",
      " .pdf).\n",
      "17.\n",
      " Karlberg J, Chong DSY, Lai WYY. Do \n",
      "men have a higher case fatality rate of se\n",
      "-vere acute respiratory syndrome than \n",
      "women do? Am J Epidemiol 2004;\n",
      " \n",
      "159:\n",
      " \n",
      "229-\n",
      "31.\n",
      " n engl j med \n",
      "nejm.org 8The\n",
      " new england journal \n",
      "of medicine\n",
      "18.\n",
      " Klein SL, Flanagan KL. Sex differenc\n",
      "-es in immune responses. Nat Rev Immu\n",
      "-nol 2016;\n",
      " 16:\n",
      " 626-38.\n",
      "19.\n",
      " Channappanavar R, Fett C, Mack M, \n",
      "Ten Eyck PP, Meyerholz DK, Perlman S. \n",
      "Sex-based differences in susceptibility to \n",
      "severe acute respiratory syndrome coro\n",
      "-navirus infection. J Immunol 2017;\n",
      " \n",
      "198:\n",
      " 4046-53.\n",
      "20.\n",
      " Siddiqi HK, Mehra MR. COVID-19 ill\n",
      "-ness in native and immunosuppressed \n",
      "states: a clinical-therapeutic staging propos\n",
      "-al. J Heart Lung Transplant 2020;\n",
      " \n",
      "39:\n",
      " \n",
      "405-7.\n",
      "21.\n",
      " Wang K, Gheblawi M, Oudit GY. An\n",
      "-giotensin converting enzyme 2: a double-\n",
      "edged sword. Circulation 2020 March 26 \n",
      "(Epub ahead of print).\n",
      "22.\n",
      " Mehra MR, Ruschitzka F. COVID-19 \n",
      "illness and heart failure: a missing link? \n",
      "JACC Heart Fail (in press).\n",
      "Copyright © 2020 Massachusetts Medical Society.\n"
     ]
    }
   ],
   "source": [
    "\n",
    "data=textacy.preprocessing.normalize.normalize_whitespace(text)\n",
    "\n",
    "print(data)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "n engl j med \n",
      "nejm.org 1From Brigham and Women™s Hospital \n",
      "Heart and Vascular Center and Harvard \n",
      "Medical School, Boston (M.R.M.); Surgi\n",
      "-sphere, Chicago (S.S.D.); Baylor College of \n",
      "Medicine and Department of Veterans Af\n",
      "-fairs, Houston (S.K.); Christ Hospital, Cin\n",
      "-cinnati (T.D.H.); the Department of Bio\n",
      "-medical Engineering, University of Utah, \n",
      "Salt Lake City (A.N.P.); and HCA Research \n",
      "Institute, Nashville (A.N.P.). Address re\n",
      "-print requests to Dr. Mehra at Brigham \n",
      "and Women™s Hospital, 75 Francis St., \n",
      "Boston, MA 02115, or at \n",
      " \n",
      "mmehra@\n",
      " \n",
      "bwh\n",
      " . harvard\n",
      " . edu.\n",
      "This article was published on May 1, 2020, \n",
      "and updated on May 8, 2020, at NEJM.org.\n",
      "DOI:˜10.1056/NEJMoa2007621\n",
      "Copyright © 2020 Massachusetts Medical Society.BACKGROUND\n",
      "Coronavirus disease 2019 (Covid-19) may disproportionately affect people with \n",
      "cardiovascular disease. Concern has been aroused regarding a potential harmful \n",
      "effect of angiotensin-convertingŒenzyme (ACE) inhibitors and angiotensin-recep\n",
      "-tor blockers (ARBs) in this clinical context.\n",
      "METHODS\n",
      "Using an observational database from 169 hospitals in Asia, Europe, and North \n",
      "America, we evaluated the relationship of cardiovascular disease and drug therapy \n",
      "with in-hospital death among hospitalized patients with Covid-19 who were admit\n",
      "-ted between December 20, 2019, and March 15, 2020, and were recorded in the \n",
      "Surgical Outcomes Collaborative registry as having either died in the hospital or \n",
      "survived to discharge as of March 28, 2020.\n",
      "RESULTS\n",
      "Of the 8910 patients with Covid-19 for whom discharge status was available at the \n",
      "time of the analysis, a total of 515 died in the hospital (5.8%) and 8395 survived \n",
      "to discharge. The factors we found to be independently associated with an in\n",
      "-creased risk of in-hospital death were an age greater than 65 years (mortality of \n",
      "10.0%, vs. 4.9% among those ˜65 years of age; odds ratio, 1.93; 95% confidence \n",
      "interval [CI], 1.60 to 2.41), coronary artery disease (10.2%, vs. 5.2% among those \n",
      "without disease; odds ratio, 2.70; 95% CI, 2.08 to 3.51), heart failure (15.3%, vs. \n",
      "5.6% among those without heart failure; odds ratio, 2.48; 95% CI, 1.62 to 3.79), \n",
      "cardiac arrhythmia (11.5%, vs. 5.6% among those without arrhythmia; odds ratio, \n",
      "1.95; 95% CI, 1.33 to 2.86), chronic obstructive pulmonary disease (14.2%, vs. \n",
      "5.6% among those without disease; odds ratio, 2.96; 95% CI, 2.00 to 4.40), and \n",
      "current smoking (9.4%, vs. 5.6% among former smokers or nonsmokers; odds \n",
      "ratio, 1.79; 95% CI, 1.29 to 2.47). No increased risk of in-hospital death was found \n",
      "to be associated with the use of ACE inhibitors (2.1% vs. 6.1%; odds ratio, 0.33; \n",
      "95% CI, 0.20 to 0.54) or the use of ARBs (6.8% vs. 5.7%; odds ratio, 1.23; 95% CI, \n",
      "0.87 to 1.74).\n",
      "CONCLUSIONS\n",
      "Our study confirmed previous observations suggesting that underlying cardiovascu\n",
      "-lar disease is associated with an increased risk of in-hospital death among patients \n",
      "hospitalized with Covid-19. Our results did not confirm previous concerns regarding \n",
      "a potential harmful association of ACE inhibitors or ARBs with in-hospital death in \n",
      "this clinical context. (Funded by the William Harvey Distinguished Chair in Ad\n",
      "-vanced Cardiovascular Medicine at Brigham and Women™s Hospital.)\n",
      "ABSTRACT\n",
      "Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19Mandeep R. Mehra, M.D., Sapan\n",
      " S. Desai, M.D., Ph.D., \n",
      "SreyRam Kuy, M.D., M.H.S., Timothy\n",
      " D. Henry, M.D., and Amit\n",
      " N. Patel, M.D.\n",
      " \n",
      "Original Article\n",
      " n engl j med \n",
      "nejm.org 2The\n",
      " new england journal \n",
      "of medicine\n",
      "As the coronavirus disease 2019 \n",
      "(Covid-19) pandemic has spread around \n",
      "the globe, there has been growing recog\n",
      "-nition that persons with underlying increased \n",
      "cardiovascular risk may be disproportionately \n",
      "affected.\n",
      "1-3\n",
      " Several studies of case series have \n",
      "noted cardiac arrhythmias, cardiomyopathy, and \n",
      "cardiac arrest as terminal events in patients with \n",
      "Covid-19.\n",
      "1-4\n",
      " Higher incidences of cardiac arrhyth\n",
      "-mias, acute coronary syndromes, and heart fail\n",
      "-ureŒrelated events have also been reported during \n",
      "seasonal influenza outbreaks, which suggests that \n",
      "acute respiratory infections may result in activa\n",
      "-tion of coagulation pathways, proinflammatory \n",
      "effects, and endothelial cell dysfunction.\n",
      "5 In ad\n",
      "-dition, however, concern has been expressed that \n",
      "medical therapy for cardiovascular disease might \n",
      "specifically contribute to the severity of illness \n",
      "in patients with Covid-19.\n",
      "6,7\n",
      "Severe acute respiratory syndrome coronavirus \n",
      "2 (SARS-CoV-2), the causative agent of Covid-19, \n",
      "has been shown to establish itself in the host \n",
      "through the use of angiotensin-converting en\n",
      "-zyme 2 (ACE2) as its cellular receptor.\n",
      "8 ACE2 is \n",
      "a membrane-bound monocarboxypeptidase found \n",
      "ubiquitously in humans and expressed predomi\n",
      "-nantly in heart, intestine, kidney, and pulmonary \n",
      "alveolar (type II) cells.\n",
      "7,9\n",
      " Entry of SARS-CoV-2 \n",
      "into human cells is facilitated by the interaction \n",
      "of a receptor-binding domain in its viral spike \n",
      "glycoprotein ectodomain with the ACE2 receptor.\n",
      "10ACE2 is counterregulatory to the activity of \n",
      "angiotensin II generated through ACE1 and is \n",
      "protective against detrimental activation of the \n",
      "reninŒangiotensinŒaldosterone system. Angioten\n",
      "-sin II is catalyzed by ACE2 to angiotensin-(1Œ7), \n",
      "which exerts vasodilatory, antiinflammatory, an\n",
      "-tifibrotic, and antigrowth effects.\n",
      "11 It has been \n",
      "suggested that ACE inhibitors and angiotensin-\n",
      "receptor blockers (ARBs) may increase the expres\n",
      "-sion of ACE2, which has been shown in the heart \n",
      "in rats,\n",
      "12 and thereby may confer a predisposition \n",
      "to more severe infection and adverse outcomes \n",
      "during Covid-19.\n",
      "6,7\n",
      " Others have suggested that \n",
      "ACE inhibitors may counter the antiinflammatory \n",
      "effects of ACE2. However, in vitro studies have \n",
      "not shown direct inhibitory activity of ACE in\n",
      "-hibitors against ACE2 function.\n",
      "9,13\n",
      "Despite these uncertainties, some have rec\n",
      "-ommended cessation of treatment with ACE in\n",
      "-hibitors and ARBs in patients with Covid-19.\n",
      "6 However, several scientific societies, including \n",
      "the American Heart Association, the American \n",
      "College of Cardiology, the Heart Failure Society \n",
      "of America, and the Council on Hypertension of \n",
      "the European Society of Cardiology, have urged \n",
      "that these important medications should not be \n",
      "discontinued in the absence of clear clinical evi\n",
      "-dence of harm.\n",
      "14,15\n",
      " We therefore undertook a study \n",
      "to investigate the relationship between underlying \n",
      "cardiovascular disease and Covid-19 outcomes and \n",
      "to evaluate the association between cardiovascular \n",
      "drug therapy and mortality in this illness.\n",
      "Methods\n",
      "Data Source\n",
      "We analyzed deidentified data from the Surgical \n",
      "Outcomes Collaborative (Surgisphere), an interna\n",
      "-tional registry. Our analysis included data from \n",
      "169 hospitals located in 11 countries in Asia, \n",
      "Europe, and North America. The collaborative uses \n",
      "automated extraction of data from inpatient and \n",
      "outpatient electronic health records, supply-chain \n",
      "databases, and financial records, combined with \n",
      "point-of-care data entry for procedures. A manual \n",
      "data-entry process is used for quality assurance \n",
      "and validation. Data are collected through auto\n",
      "-mated data transfers that capture information \n",
      "from each health care entity at regular intervals \n",
      "on a prospective, ongoing basis. Verifiable source \n",
      "documentation for the data elements includes elec\n",
      "-tronic inpatient and outpatient medical records.\n",
      "Data acquisition is facilitated through the use \n",
      "of a standardized Health Level SevenŒcompliant \n",
      "data dictionary. After this data dictionary is har\n",
      "-monized with data from electronic health records, \n",
      "the majority of the data acquisition is completed \n",
      "with automated interfaces. The collected data \n",
      "sample from each health care entity is validated \n",
      "against financial records and external databas\n",
      "-es. All protected health information is stripped \n",
      "from each record before storage in a cloud-based \n",
      "data warehouse. The collaborative is compliant \n",
      "with the Agency for Healthcare Research and \n",
      "Quality guidelines for registries and the Food and \n",
      "Drug Administration guidance on real-world evi\n",
      "-dence. The collection and analysis of data in the \n",
      "registry have been deemed exempt from ethics \n",
      "review.\n",
      "Data Collection\n",
      "The collaborative registry was used as a resource \n",
      "to analyze data from all patients with polymerase-\n",
      " n engl j med \n",
      "nejm.org 3Cardiovascular Disease in Covid-19\n",
      "chain-reaction (PCR)Œproven Covid-19 who were \n",
      "admitted to the hospital between December 20, \n",
      "2019, and March 15, 2020, and who were re\n",
      "-corded in the registry as having either died in \n",
      "the hospital or survived to hospital discharge as \n",
      "of March 28, 2020. Data from the registry can be \n",
      "analyzed only after a patient™s hospitalization is \n",
      "complete, and therefore our sample did not in\n",
      "-clude patients who were admitted to the hospital \n",
      "during this time window but were still hospital\n",
      "-ized at the end of it. Our sample also may have \n",
      "excluded some patients who had died or were \n",
      "discharged by March 28 but whose discharge \n",
      "status had not yet been recorded by the hospital.\n",
      "The presence in the record of a positive labo\n",
      "-ratory finding confirming SARS-CoV-2 infection \n",
      "was used for classifying a patient as positive for \n",
      "Covid-19. A positive laboratory finding for SARS-\n",
      "CoV-2 was defined as a positive result on high-\n",
      "throughput sequencing or real-time reverse-tran\n",
      "-scriptaseŒPCR (RT-PCR) assay of nasal or \n",
      "pharyngeal swab specimens. At each site, Covid-19 \n",
      "was diagnosed on the basis of the World Health \n",
      "Organization guidance.\n",
      "16 Patients who did not \n",
      "undergo testing, had no record of testing in the \n",
      "collaborative database, or had a negative test \n",
      "were not included in the present study. For this \n",
      "study, only one positive test was necessary for \n",
      "the patient to be included in the analysis.\n",
      "Data on patients™ demographic characteris\n",
      "-tics, coexisting conditions (based on codes from \n",
      "the \n",
      "International Classification of Diseases, 10th Revi\n",
      "-sion, Clinical Modification\n",
      "), and cardiovascular drug \n",
      "therapy were included in this analysis. Clinical \n",
      "information included age, sex, continent of ori\n",
      "-gin, and underlying coexisting conditions as \n",
      "noted in either the inpatient or the outpatient \n",
      "electronic health record. Coexisting conditions \n",
      "included chronic obstructive pulmonary disease \n",
      "(COPD), an immunosuppressed condition (glu\n",
      "-cocorticoid use, a preexisting immunologic con\n",
      "-dition, or ongoing chemotherapy in patients \n",
      "with cancer), current or remote history of smok\n",
      "-ing, and a history of hypertension, diabetes mel\n",
      "-litus, hyperlipidemia, or underlying cardiovascu\n",
      "-lar disease (including coronary artery disease, \n",
      "heart failure, and cardiac arrhythmia). Cardio\n",
      "-vascular drug therapy recorded at the time of \n",
      "hospital admission was also included, including \n",
      "any antiplatelet therapy, use of insulin or other \n",
      "hypoglycemic agents, beta-blockers, statins, ARBs, \n",
      "and ACE inhibitors.\n",
      "All the authors reviewed the manuscript and \n",
      "vouch for the accuracy and completeness of the \n",
      "data provided.\n",
      "Statistical Analysis\n",
      "The primary analysis was an evaluation of the \n",
      "relationship of preexisting cardiovascular dis\n",
      "-ease and drug therapy with the end point of in-\n",
      "hospital death while controlling for confound\n",
      "-ers, including demographic characteristics and \n",
      "coexisting conditions. Categorical variables are \n",
      "shown as frequencies and percentages, and con\n",
      "-tinuous variables as means and standard devia\n",
      "-tions. Independent sample t-tests were complet\n",
      "-ed, and point differences with 95% confidence \n",
      "intervals are reported for all comparisons be\n",
      "-tween variables. Multiple imputation for missing \n",
      "values was not possible because for disease and \n",
      "drug variables there were no codes to indicate \n",
      "that data were missing; if the patient™s elec\n",
      "-tronic health record did not include information \n",
      "on a clinical characteristic, such as hyperlipid\n",
      "-emia or the use of beta-blockers, it was assumed \n",
      "that that characteristic was not present.\n",
      "A multivariable logistic-regression analysis \n",
      "was performed to ascertain the effects of age, \n",
      "race, coexisting conditions (coronary artery dis\n",
      "-ease, congestive heart failure, cardiac arrhyth\n",
      "-mia, diabetes mellitus, COPD, current smoking, \n",
      "former smoking, hypertension, immunocompro\n",
      "-mised state, and hyperlipidemia), hospital loca\n",
      "-tion (according to country), and medications \n",
      "(ACE inhibitors, ARBs, beta-blockers, antiplate\n",
      "-let agents, statins, insulin, and oral hypoglyce\n",
      "-mic agents) on the likelihood of in-hospital \n",
      "death. Linearity of the continuous variables with \n",
      "respect to the logit of the dependent variable was \n",
      "confirmed. Odds ratios and corresponding 95% \n",
      "confidence intervals were calculated. Separate \n",
      "age- and sex-adjusted analyses were also per\n",
      "-formed. The 95% confidence intervals have not \n",
      "been adjusted for multiple testing and should \n",
      "not be used to infer definitive effects.\n",
      "On the basis of the results of the initial \n",
      "analyses, additional analyses were performed to \n",
      "examine the robustness of the estimates initially \n",
      "obtained. Analyses according to continent of ori\n",
      "-gin as well as country classification (as either high \n",
      "income or lowŒmiddle income) were performed. \n",
      "A tipping-point analysis (an analysis that shows \n",
      "the effect size and prevalence of an unmeasured \n",
      "confounder that could shift the upper boundary \n",
      " n engl j med \n",
      "nejm.org 4The\n",
      " new england journal \n",
      "of medicine\n",
      "of the confidence interval toward null) was per\n",
      "-formed. In addition, we sought to determine \n",
      "whether the effect of ACE inhibitors and statins \n",
      "noted in the overall study was also seen when \n",
      "the analysis was confined to a subgroup of pa\n",
      "-tients who might have an indication for these \n",
      "agents. Thus, the association of ACE inhibitor \n",
      "use with in-hospital death was examined in the \n",
      "subgroup of patients with hypertension, and the \n",
      "association of statin use with in-hospital death \n",
      "was examined in the subgroup of patients with \n",
      "hyperlipidemia, with the use of age- and sex-\n",
      "adjusted logistic-regression analysis. All statistical \n",
      "analyses were performed with R software, version \n",
      "3.6.3 (R Foundation for Statistical Computing), \n",
      "and SPSS Statistics software, version 26 (IBM).\n",
      "Results\n",
      "Patients\n",
      "Our study population included 8910 hospitalized \n",
      "patients from 169 hospitals who had Covid-19, \n",
      "who were admitted between December 20, 2019, \n",
      "and March 15, 2020, and who completed their \n",
      "hospital course (discharged alive or died) by March \n",
      "28, 2020. Patients who were hospitalized during \n",
      "this time without a completed course could not \n",
      "be included in the analysis. Our sample was \n",
      "made up of 1536 patients (17.2%) from North \n",
      "America, 5755 (64.6%) from Europe, and 1619 \n",
      "(18.2%) from Asia (details of the study popula\n",
      "-tion according to continent, country, and num\n",
      "-ber of hospitals are provided in Table S1 in the \n",
      "Supplementary Appendix, available with the full \n",
      "text of this article at NEJM.org). The mean (±SD) \n",
      "age was 49±16 years (16.5% of the patients were \n",
      ">65 years of age), 40.0% of the patients were \n",
      "women, 63.5% were white, 7.9% were black, 6.3% \n",
      "were Hispanic, and 19.3% were Asian.\n",
      "With respect to cardiovascular risk factors, \n",
      "30.5% of the patients had hyperlipidemia, 26.3% \n",
      "had hypertension, 14.3% had diabetes mellitus, \n",
      "16.8% were former smokers, and 5.5% were cur\n",
      "-rent smokers. Preexisting cardiovascular disease \n",
      "in this sample included coronary artery disease \n",
      "(present in 11.3% of the patients), a history of con\n",
      "-gestive heart failure (2.1%), and a history of cardiac \n",
      "arrhythmia (3.4%). Other coexisting conditions \n",
      "included COPD (in 2.5% of the patients) and an \n",
      "underlying immunosuppressed condition (2.8%). \n",
      "Medical therapy included ACE inhibitors (8.6% \n",
      "of the patients), ARBs (6.2%), statins (9.7%), \n",
      "beta-blockers (5.9%), and antiplatelet agents (3.3%). \n",
      "Insulin was used in 3.4% of the patients, and \n",
      "other hypoglycemic agents were used in 9.6%. \n",
      "The mean length of hospital stay was 10.7±2.7 \n",
      "days, with an overall in-hospital mortality of \n",
      "5.8% (515 of 8910 patients) in this population of \n",
      "patients with completed outcomes. Of the pa\n",
      "-tients who had been admitted to an intensive care \n",
      "unit (ICU) at any time during their hospitaliza\n",
      "-tion, 24.7% died, as compared with 4.0% of the \n",
      "patients who had not been admitted to an ICU.\n",
      "Analysis of Survivors as Compared \n",
      " with Nonsurvivors\n",
      "Table\n",
      " 1 shows the distribution of demographic \n",
      "characteristics and coexisting conditions among \n",
      "survivors and nonsurvivors, along with the be\n",
      "-tween-group differences and 95% confidence in\n",
      "-tervals. Nonsurvivors were older, more likely to be \n",
      "white, and more often men, and they had a \n",
      "greater prevalence of diabetes mellitus, hyperlip\n",
      "-idemia, coronary artery disease, heart failure, \n",
      "and cardiac arrhythmias. Patients who died were \n",
      "also more likely to have had COPD and a history \n",
      "of current smoking. Among medications, ACE in\n",
      "-hibitors and statins were more commonly used by \n",
      "survivors than by nonsurvivors (Table\n",
      " 2), whereas \n",
      "no association between survival and the use of \n",
      "ARBs was found. The length of hospital stay dif\n",
      "-fered between survivors and nonsurvivors (10.5±2.5 \n",
      "days vs. 7.5±2.8 days). When the data were ana\n",
      "-lyzed according to age decile, continent, or in\n",
      "-come category of the country in which the hos\n",
      "-pital was located (high income or lowŒmiddle \n",
      "income), the results were similar (Fig. S1 and \n",
      "Tables S2 and S3).\n",
      "Multivariable Logistic-Regression Analysis\n",
      "A multivariable logistic-regression model was \n",
      "developed. Independent predictors of in-hospital \n",
      "death and their corresponding odds ratios and \n",
      "95% confidence intervals are shown in Figure\n",
      " 1. \n",
      "An age greater than 65 years, coronary artery \n",
      "disease, congestive heart failure, cardiac arrhyth\n",
      "-mia, COPD, and current smoking were associat\n",
      "-ed with a higher risk of in-hospital death. Fe\n",
      "-male sex, the use of ACE inhibitors, and the use \n",
      "of statins were associated with a better chance \n",
      "of survival to hospital discharge, with no associa\n",
      "-tion found for the use of ARBs. For female sex, \n",
      " n engl j med \n",
      "nejm.org 5Cardiovascular Disease in Covid-19\n",
      "the odds ratio for dying in the hospital was 0.79 \n",
      "(95% confidence interval [CI], 0.65 to 0.95); for \n",
      "ACE inhibitor use, the odds ratio was 0.33 (95% \n",
      "CI, 0.20 to 0.54); and for statin use, the odds \n",
      "ratio was 0.35 (95% CI, 0.24 to 0.52). For ARB \n",
      "use, the odds ratio was 1.23 (95% CI, 0.87 to \n",
      "1.74). The presence or absence of an immuno\n",
      "-suppressed condition, the race or ethnic group, \n",
      "and the presence or absence of hyperlipidemia \n",
      "or diabetes mellitus were not independent pre\n",
      "-dictors of death in the hospital. The analyses \n",
      "according to continent and according to the in\n",
      "-come category of the country (high or lowŒmiddle) \n",
      "were consistent with the overall results (Tables \n",
      "S4 and S5). Data from the age- and sex-adjusted \n",
      "multivariable logistic-regression analyses are \n",
      "shown in Table S6.\n",
      "Table˜1.\n",
      "˜Demographic˜Characteristics˜and˜Coexisting˜Conditions˜among˜Survivors˜and˜Nonsurvivors˜of˜Covid-19.*\n",
      "Characteristic˜or˜Condition\n",
      "Survivors˜(N˜=˜8395)Nonsurvivors˜(N˜=˜515)Difference˜(95%˜CI)ƒ\n",
      "Age Š yr\n",
      "48.7±16.655.8±15.1˜7.1 (˜8.4 to ˜5.7)\n",
      "Age >65 yr Š no. (%)\n",
      "1327 (15.8)\n",
      "147 (28.5)\n",
      "˜12.7 (˜16.0 to ˜9.4)\n",
      "Female sex Š no. (%)\n",
      "3392 (40.4)\n",
      "179 (34.8)\n",
      "5.6 (1.3 to 10.0)\n",
      "Race or ethnic group Š no. (%)⁄\n",
      "White5306 (63.2)\n",
      "351 (68.2)\n",
      "˜5.0 (˜9.1 to ˜0.8)\n",
      "Black672 (8.0)\n",
      "34 (6.6)\n",
      "1.4 (˜0.8 to 3.6)\n",
      "Hispanic529 (6.3)\n",
      "32 (6.2)\n",
      "0.1 (˜2.0 to 2.3)\n",
      "Asian1637 (19.5)\n",
      "84 (16.3)\n",
      "3.2 (˜0.2 to 6.5)\n",
      "Native American\n",
      "34 (0.4)\n",
      "1 (0.2)\n",
      "0.2 (˜0.3 to 0.8)\n",
      "Other219 (2.6)\n",
      "13 (2.5)\n",
      "0.1 (˜1.4 to 1.4)\n",
      "Coexisting conditions Š no. (%)\n",
      "Coronary artery disease\n",
      "907 (10.8)\n",
      "103 (20.0)\n",
      "˜9.2 (˜12.8 to ˜5.7)\n",
      "Congestive heart failure\n",
      "160 (1.9)\n",
      "29 (5.6)\n",
      "˜3.7 (˜5.8 to ˜1.8)\n",
      "Cardiac arrhythmia269 (3.2)\n",
      "35 (6.8)\n",
      "˜3.6 (˜5.8 to ˜1.4)\n",
      "Diabetes mellitus\n",
      "1175 (14.0)\n",
      "97 (18.8)\n",
      "˜4.8 (˜8.3 to ˜1.3)\n",
      "Hypertension2216 (26.4)\n",
      "130 (25.2)\n",
      "1.2 (˜2.8 to 5.1)\n",
      "Hyperlipidemia2535 (30.2)\n",
      "180 (35.0)\n",
      "˜4.8 (˜9.0 to ˜0.5)\n",
      "COPD193 (2.3)\n",
      "32 (6.2)\n",
      "˜3.9 (˜6.1 to ˜1.8)\n",
      "Current smoker\n",
      "445 (5.3)\n",
      "46 (8.9)\n",
      "˜3.6 (˜6.2 to ˜1.1)\n",
      "Former smoker\n",
      "1410 (16.8)\n",
      "83 (16.1)\n",
      "0.7 (˜2.6 to 4.0)\n",
      "Immunosuppressed condition\n",
      "227 (2.7)\n",
      "22 (4.3)\n",
      "˜1.6 (˜3.4 to 0.2)\n",
      "* \n",
      "PlusŒminus values are means ±SD. The 95% confidence intervals (CIs) have not been adjusted for multiple testing and should not be used to infer definitive effects. COPD denotes chronic obstructive pulmonary disease, and Covid-19 coro-navirus disease 2019.ƒ \n",
      "For mean age, the difference is given in years; for all other characteristics, the difference is given in percentage points.⁄ \n",
      "Race and ethnic group were reported by the patient.Table˜2.\n",
      "˜Cardiovascular˜Drug˜Therapy˜at˜Hospitalization˜among˜Survivors˜\n",
      "˜and˜Nonsurvivors˜of˜Covid-19.*\n",
      "Drug˜Class\n",
      "Survivors˜(N˜=˜8395)Nonsurvivors˜(N˜=˜515)Difference˜(95%˜CI)\n",
      "number (percent)\n",
      "percentage points\n",
      "ACE inhibitor\n",
      "754 (9.0)\n",
      "16 (3.1)\n",
      "5.9 (4.3 to 7.5)\n",
      "ARB518 (6.2)\n",
      "38 (7.4)\n",
      "˜1.2 (˜3.5 to 1.1)\n",
      "Beta-blocker497 (5.9)\n",
      "28 (5.4)\n",
      "0.5 (˜1.6 to 2.6)\n",
      "Antiplatelet282 (3.4)\n",
      "13 (2.5)\n",
      "0.8 (˜0.6 to 2.2)\n",
      "Statin824 (9.8)\n",
      "36 (7.0)\n",
      "2.8 (0.5 to 5.1)\n",
      "Insulin279 (3.3)\n",
      "23 (4.5)\n",
      "˜1.2 (˜3.0 to 0.7)\n",
      "Other hypoglycemic agent792 (9.4)\n",
      "59 (11.5)\n",
      "˜2.1 (˜4.9 to 0.8)\n",
      "* \n",
      "The 95% confidence intervals have not been adjusted for multiple testing and should not be used to infer definitive effects. ACE denotes angiotensin-converting enzyme, and ARB angiotensin-receptor blocker. n engl j med \n",
      "nejm.org 6The\n",
      " new england journal \n",
      "of medicine\n",
      "Additional Analyses\n",
      "In the tipping-point analysis to assess the poten\n",
      "-tial effect of an unmeasured confounder, it was \n",
      "estimated that a hypothetical unobserved binary \n",
      "confounder with a prevalence of 10% in the study \n",
      "population would need to have an odds ratio of \n",
      "at least 10 in order for the observed associations \n",
      "for either ACE inhibitors or statins to have 95% \n",
      "confidence intervals crossing the odds ratio \n",
      "boundary of 1.0 (Table S7). We also separately \n",
      "examined the interaction of ACE inhibitor use \n",
      "with mortality in the subgroup with hyperten\n",
      "-sion and the interaction of statin use with mor\n",
      "-tality in the subgroup with hyperlipidemia. These \n",
      "analyses, shown in Table S8, are consistent with \n",
      "the results of the primary analysis.\n",
      "Discussion\n",
      "Our investigation confirms previous reports of \n",
      "the independent relationship of older age, under\n",
      "-lying cardiovascular disease (coronary artery dis\n",
      "-ease, heart failure, and cardiac arrhythmias), cur\n",
      "-rent smoking, and COPD with death in Covid-19. \n",
      "Our results also suggest that women are propor\n",
      "-tionately more likely than men to survive the \n",
      "infection. Neither harmful nor beneficial asso\n",
      "-ciations were noted for antiplatelet therapy, beta-\n",
      "blockers, or hypoglycemic therapy. It is important \n",
      "to note that we were not able to confirm previous \n",
      "concerns regarding a potential harmful associa\n",
      "-tion of either ACE inhibitors or ARBs with in-\n",
      "hospital mortality in this clinical context.\n",
      "In viral infections such as influenza, older \n",
      "age is associated with an increased risk of car\n",
      "-diovascular events and death.\n",
      "5 In the 2003 epi\n",
      "-demic of severe acute respiratory syndrome \n",
      "(SARS, caused by SARS-CoV-1 infection), sex \n",
      "differences in the risk of death similar to those \n",
      "we observed were noted.\n",
      "17 Women have stronger \n",
      "innate and adaptive immunity and greater resis\n",
      "-tance to viral infections than men.\n",
      "18 In animal \n",
      "models of SARS-CoV-1 infection, higher suscep\n",
      "-tibility of male mice to SARS-CoV-1 and greater \n",
      "accumulation of macrophages and neutrophils \n",
      "in the lungs have been described.\n",
      "19 Ovariectomy \n",
      "or the use of estrogen-receptor antagonists \n",
      "increased mortality from SARS-CoV-1 infection \n",
      "in female animals. Furthermore, the difference in \n",
      "risk between the sexes increased with advancing \n",
      "age.\n",
      "19 These findings may support the observa\n",
      "-tion in our investigation that suggested an as\n",
      "-sociation between survival and female sex, inde\n",
      "-pendent of older age.\n",
      "Infection with SARS-CoV-2 is a mild disease \n",
      "in most people, but in some the disease pro\n",
      "-gresses to a severe respiratory illness character\n",
      "-ized by a hyperinflammatory syndrome, multi\n",
      "-organ dysfunction, and death.\n",
      "20 In the lung, the \n",
      "viral spike glycoprotein of SARS-CoV-2 interacts \n",
      "with cell-surface ACE2, and the virus is internal\n",
      "-ized by endocytosis. The endocytic event up-\n",
      "regulates the activity of ADAM metallopeptidase \n",
      "domain 17 (ADAM17), which cleaves ACE2 from \n",
      "the cell membrane, resulting in a loss of ACE2-\n",
      "mediated protection against the effects of activa\n",
      "-Figure˜1.\n",
      "˜Independent˜Predictors˜of˜In-Hospital˜Death˜from˜Multivariable˜Logistic-Regression˜Analysis.\n",
      "Numbers and percentages of patients with each risk factor who died (risk factor present) and of patients without each risk factor who \n",
      "died (risk factor absent) are shown. The 95% confidence intervals (CIs) of the odds ratios have not been adjusted for multiple testing \n",
      "and should not be used to infer definitive effects. ACE denotes angiotensin-converting enzyme, ARB angiotensin-receptor blocker, and \n",
      "COPD chronic obstructive pulmonary disease.\n",
      "˜˚˛˜˛˚˛ˇˇˇ˜˛–•˜˛˜˛ˇ‡˜˛˚ƒ…ˇˇƒ—•˜⁄—ˇ‡˜ˆ˚–…ˇˇ–ˆ•–˛€ˇ‡˜˜˚ˆ…ˇˇ–ƒ•ƒƒˆˇ‡˜€˚ƒ…€˙•€—˜ˇ‡—˚€…–⁄•ˆˆ˙ˇ‡˙˚⁄…–˙•⁄˙˛ˇ‡€˚ƒ…––˙•ˆ––—ˇ‡˙˚–…€⁄˛•⁄˙˛˙ˇ‡ˆ˚˙…€⁄–•⁄˙⁄ˆˇ‡ˆ˚˙…€˙—•⁄€˜—ˇ‡ˆ˚˙…€——•⁄˜€˛ˇ‡˙˚˜…˜˚—–ˇ‡˜˚˙˛‹ƒ˚€˜…ˆ‹˛˚—ˆ…⁄‹–˚ˆ˜…ƒ˚€⁄ˇ‡˜˚˙ƒ‹˜˚—ˆˇ‡˜˚––‹ƒ˚⁄˙…ƒ˚—˙ˇ‡ƒ˚˛˛‹€˚€˛…—‹˛˚––ˇ‡˛˚ƒ˛‹˛˚ˆ€…˜˚ƒ–ˇ‡˛˚⁄˛˚–ˆˇ‡˛˚ƒ€‹˛˚ˆƒ…˛˚˜ n engl j med \n",
      "nejm.org 7Cardiovascular Disease in Covid-19\n",
      "tion of the tissue reninŒangiotensinŒaldosterone \n",
      "system while mediating the release of proin\n",
      "-flammatory cytokines into the circulation.\n",
      "21 The \n",
      "stress of critical illness and inflammation may \n",
      "unite in destabilizing preexisting cardiovascular \n",
      "illness. Vascular endothelial cell dysfunction, in\n",
      "-flammation-associated myocardial depression, \n",
      "stress cardiomyopathy, direct viral infection of \n",
      "the heart and its vessels, or the host response may \n",
      "cause or worsen heart failure, demand-related isch\n",
      "-emia, and arrhythmias.\n",
      "22 These factors may under\n",
      "-lie the observed associations between cardiovascu\n",
      "-lar disease and death in Covid-19.\n",
      "In our analyses, use of either ACE inhibitors \n",
      "or statins was associated with better survival \n",
      "among patients with Covid-19. However, these as\n",
      "-sociations should be considered with extreme cau\n",
      "-tion. Because our study was not a randomized, \n",
      "controlled trial, we cannot exclude the possibility \n",
      "of confounding. In addition, we examined rela\n",
      "-tionships between many variables and in-hospi\n",
      "-tal death, and no primary hypothesis was pre\n",
      "-specified; these factors increased the probability \n",
      "of chance associations being found. Therefore, a \n",
      "cause-and-effect relationship between drug ther\n",
      "-apy and survival should not be inferred. These \n",
      "data also offer no information concerning the \n",
      "potential effect of initiation of ACE inhibitor or \n",
      "statin therapy in patients with Covid-19 who do \n",
      "not have an appropriate indication for these \n",
      "medications. Randomized clinical trials evaluat\n",
      "-ing the role of ACE inhibitors and statins will be \n",
      "necessary before any conclusion can be reached \n",
      "regarding a potential benefit of these agents in \n",
      "patients with Covid-19.\n",
      "In this multinational observational study in\n",
      "-volving patients hospitalized with Covid-19, we \n",
      "confirmed previous observations suggesting that \n",
      "underlying cardiovascular disease is independently \n",
      "associated with an increased risk of in-hospital \n",
      "death. We were not able to confirm previous con\n",
      "-cerns regarding a potential harmful association \n",
      "of ACE inhibitors or ARBs with in-hospital mor\n",
      "-tality in this clinical context.\n",
      "Supported by the William Harvey Distinguished Chair in \n",
      "Advanced Cardiovascular Medicine at Brigham and Women™s \n",
      "Hospital. The development and maintenance of the Surgical \n",
      "Outcomes Collaborative database was funded by Surgisphere.\n",
      "Disclosure forms provided by the authors are available with \n",
      "the full text of this article at NEJM.org.\n",
      "References\n",
      "1. Ruan Q, Yang K, Wang W, Jiang L, \n",
      "Song J. Clinical predictors of mortality \n",
      "due to COVID-19 based on an analysis of \n",
      "data of 150 patients from Wuhan, China. \n",
      "Intensive Care Med 2020 March 3 (Epub \n",
      "ahead of print).\n",
      "2. Shi S, Qin M, Shen B, et al. Associa\n",
      "-tion of cardiac injury with mortality in \n",
      "hospitalized patients with COVID-19 in \n",
      "Wuhan, China. JAMA Cardiol 2020 March \n",
      "25 (Epub ahead of print).\n",
      "3. Guo T, Fan Y, Chen M, et al. Cardio\n",
      "-vascular implications of fatal outcomes of \n",
      "patients with coronavirus disease 2019 \n",
      "(COVID-19). JAMA Cardiol 2020 March 27 \n",
      "(Epub ahead of print).\n",
      "4. Arentz M, Yim E, Klaff L, et al. Char\n",
      "-acteristics and outcomes of 21 critically ill \n",
      "patients with COVID-19 in Washington \n",
      "State. JAMA 2020 March 19 (Epub ahead \n",
      "of print).\n",
      "5. Nguyen JL, Yang W, Ito K, Matte TD, \n",
      "Shaman J, Kinney PL. Seasonal influenza \n",
      "infections and cardiovascular disease \n",
      "mortality. JAMA Cardiol 2016;\n",
      " \n",
      "1:\n",
      " \n",
      "274-81.\n",
      "6. Fang L, Karakiulakis G, Roth M. Are \n",
      "patients with hypertension and diabetes \n",
      "mellitus at increased risk for COVID-19 \n",
      "infection? Lancet Respir Med 2020;\n",
      " \n",
      "8(4):\n",
      " e21.\n",
      "7. Nicin L, Abplanalp WT, Mellentin H, \n",
      "et al. Cell type-specific expression of the \n",
      "putative SARS-CoV-2 receptor ACE2 in hu\n",
      "-man hearts. Eur Heart J 2020 April 15 \n",
      "(Epub ahead of print).\n",
      "8. Hoffmann M, Kleine-Weber H, Schro\n",
      "-eder S, et al. SARS-CoV-2 cell entry de\n",
      "-pends on ACE2 and TMPRSS2 and is \n",
      "blocked by a clinically proven protease \n",
      "inhibitor. Cell 2020;\n",
      " 181(2):\n",
      " 271.e8-280.e8.\n",
      "9. Rice GI, Thomas DA, Grant PJ, Turner \n",
      "AJ, Hooper NM. Evaluation of angioten\n",
      "-sin-converting enzyme (ACE), its homo\n",
      "-logue ACE2 and neprilysin in angiotensin \n",
      "peptide metabolism. Biochem J 2004;\n",
      " \n",
      "383:\n",
      " 45-51.\n",
      "10.\n",
      " Walls AC, Park YJ, Tortorici MA, Wall \n",
      "A, McGuire AT, Veesler D. Structure, \n",
      "function, and antigenicity of the SARS-\n",
      "CoV-2 spike glycoprotein. Cell 2020;\n",
      " 181(2):\n",
      " 281.e6-292.e6.\n",
      "11.\n",
      " Li XC, Zhang J, Zhuo JL. The vasopro\n",
      "-tective axes of the renin-angiotensin sys\n",
      "-tem: physiological relevance and thera\n",
      "-peutic implications in cardiovascular, \n",
      "hypertensive and kidney diseases. Phar\n",
      "-macol Res 2017;\n",
      " 125:\n",
      " 21-38.\n",
      "12.\n",
      " Ferrario CM, Jessup J, Chappell MC, et \n",
      "al. Effect of angiotensin-converting en\n",
      "-zyme inhibition and angiotensin II recep\n",
      "-tor blockers on cardiac angiotensin-con\n",
      "-verting enzyme 2. Circulation 2005;\n",
      " \n",
      "111:\n",
      " 2605-10.\n",
      "13.\n",
      " Patel AB, Verma A. COVID-19 and \n",
      "angiotensin-converting enzyme inhibi\n",
      "-tors and angiotensin receptor blockers: \n",
      "what is the evidence? JAMA 2020 March \n",
      "24 (Epub ahead of print).\n",
      "14.\n",
      " American College of Cardiology. \n",
      "HFSA/ACC/AHA statement addresses \n",
      "concerns re: using RAAS antagonists in \n",
      "COVID-19. March 17, 2020 (https://www\n",
      " .acc\n",
      " .org/\n",
      " latest\n",
      " - in\n",
      " - cardiology/\n",
      " articles/\n",
      " 2020/\n",
      " 03/\n",
      " 17/\n",
      " 08/\n",
      " 59/\n",
      " hfsa\n",
      " - acc\n",
      " - aha\n",
      " - statement\n",
      " - addresses\n",
      " - concerns\n",
      " - re\n",
      " - using\n",
      " - raas\n",
      " - antagonists\n",
      " - in\n",
      " - covid\n",
      " - 19).\n",
      "15.\n",
      " European Society of Cardiology. Posi\n",
      "-tion statement of the ESC Council on Hy\n",
      "-pertension on ACE-inhibitors and angio\n",
      "-tensin receptor blockers. March 13, 2020 \n",
      "(https://www\n",
      " .escardio\n",
      " .org/\n",
      " Councils/\n",
      " Council\n",
      " - on - Hypertension\n",
      " - (CHT)/\n",
      " News/\n",
      " position\n",
      " - statement\n",
      " - of - the\n",
      " - esc\n",
      " - council\n",
      " - on - hypertension\n",
      " - on - ace\n",
      " - inhibitors\n",
      " - and\n",
      " - ang).\n",
      "16.\n",
      " World Health Organization. Clinical \n",
      "management of severe acute respiratory \n",
      "infection (SARI) when COVID-19 disease \n",
      "is suspected: interim guidance. March 13, \n",
      "2020 (https://www\n",
      " .who\n",
      " .int/\n",
      " docs/\n",
      " default\n",
      " - source/\n",
      " coronaviruse/\n",
      " clinical\n",
      " - management\n",
      " - of\n",
      " - novel\n",
      " - cov\n",
      " .pdf).\n",
      "17.\n",
      " Karlberg J, Chong DSY, Lai WYY. Do \n",
      "men have a higher case fatality rate of se\n",
      "-vere acute respiratory syndrome than \n",
      "women do? Am J Epidemiol 2004;\n",
      " \n",
      "159:\n",
      " \n",
      "229-\n",
      "31.\n",
      " n engl j med \n",
      "nejm.org 8The\n",
      " new england journal \n",
      "of medicine\n",
      "18.\n",
      " Klein SL, Flanagan KL. Sex differenc\n",
      "-es in immune responses. Nat Rev Immu\n",
      "-nol 2016;\n",
      " 16:\n",
      " 626-38.\n",
      "19.\n",
      " Channappanavar R, Fett C, Mack M, \n",
      "Ten Eyck PP, Meyerholz DK, Perlman S. \n",
      "Sex-based differences in susceptibility to \n",
      "severe acute respiratory syndrome coro\n",
      "-navirus infection. J Immunol 2017;\n",
      " \n",
      "198:\n",
      " 4046-53.\n",
      "20.\n",
      " Siddiqi HK, Mehra MR. COVID-19 ill\n",
      "-ness in native and immunosuppressed \n",
      "states: a clinical-therapeutic staging propos\n",
      "-al. J Heart Lung Transplant 2020;\n",
      " \n",
      "39:\n",
      " \n",
      "405-7.\n",
      "21.\n",
      " Wang K, Gheblawi M, Oudit GY. An\n",
      "-giotensin converting enzyme 2: a double-\n",
      "edged sword. Circulation 2020 March 26 \n",
      "(Epub ahead of print).\n",
      "22.\n",
      " Mehra MR, Ruschitzka F. COVID-19 \n",
      "illness and heart failure: a missing link? \n",
      "JACC Heart Fail (in press).\n",
      "Copyright © 2020 Massachusetts Medical Society.\n"
     ]
    }
   ],
   "source": [
    "data=textacy.preprocessing.normalize.normalize_unicode(data)\n",
    "print(data)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "n engl j med \n",
      "nejm.org 1From Brigham and WomenTMs Hospital \n",
      "Heart and Vascular Center and Harvard \n",
      "Medical School, Boston (M.R.M.); Surgi\n",
      "-sphere, Chicago (S.S.D.); Baylor College of \n",
      "Medicine and Department of Veterans Af\n",
      "-fairs, Houston (S.K.); Christ Hospital, Cin\n",
      "-cinnati (T.D.H.); the Department of Bio\n",
      "-medical Engineering, University of Utah, \n",
      "Salt Lake City (A.N.P.); and HCA Research \n",
      "Institute, Nashville (A.N.P.). Address re\n",
      "-print requests to Dr. Mehra at Brigham \n",
      "and WomenTMs Hospital, 75 Francis St., \n",
      "Boston, MA 02115, or at \n",
      " \n",
      "mmehra@\n",
      " \n",
      "bwh\n",
      " . harvard\n",
      " . edu.\n",
      "This article was published on May 1, 2020, \n",
      "and updated on May 8, 2020, at NEJM.org.\n",
      "DOI: 10.1056/NEJMoa2007621\n",
      "Copyright © 2020 Massachusetts Medical Society.BACKGROUND\n",
      "Coronavirus disease 2019 (Covid-19) may disproportionately affect people with \n",
      "cardiovascular disease. Concern has been aroused regarding a potential harmful \n",
      "effect of angiotensin-convertingŒenzyme (ACE) inhibitors and angiotensin-recep\n",
      "-tor blockers (ARBs) in this clinical context.\n",
      "METHODS\n",
      "Using an observational database from 169 hospitals in Asia, Europe, and North \n",
      "America, we evaluated the relationship of cardiovascular disease and drug therapy \n",
      "with in-hospital death among hospitalized patients with Covid-19 who were admit\n",
      "-ted between December 20, 2019, and March 15, 2020, and were recorded in the \n",
      "Surgical Outcomes Collaborative registry as having either died in the hospital or \n",
      "survived to discharge as of March 28, 2020.\n",
      "RESULTS\n",
      "Of the 8910 patients with Covid-19 for whom discharge status was available at the \n",
      "time of the analysis, a total of 515 died in the hospital (5.8%) and 8395 survived \n",
      "to discharge. The factors we found to be independently associated with an in\n",
      "-creased risk of in-hospital death were an age greater than 65 years (mortality of \n",
      "10.0%, vs. 4.9% among those  65 years of age; odds ratio, 1.93; 95% confidence \n",
      "interval [CI], 1.60 to 2.41), coronary artery disease (10.2%, vs. 5.2% among those \n",
      "without disease; odds ratio, 2.70; 95% CI, 2.08 to 3.51), heart failure (15.3%, vs. \n",
      "5.6% among those without heart failure; odds ratio, 2.48; 95% CI, 1.62 to 3.79), \n",
      "cardiac arrhythmia (11.5%, vs. 5.6% among those without arrhythmia; odds ratio, \n",
      "1.95; 95% CI, 1.33 to 2.86), chronic obstructive pulmonary disease (14.2%, vs. \n",
      "5.6% among those without disease; odds ratio, 2.96; 95% CI, 2.00 to 4.40), and \n",
      "current smoking (9.4%, vs. 5.6% among former smokers or nonsmokers; odds \n",
      "ratio, 1.79; 95% CI, 1.29 to 2.47). No increased risk of in-hospital death was found \n",
      "to be associated with the use of ACE inhibitors (2.1% vs. 6.1%; odds ratio, 0.33; \n",
      "95% CI, 0.20 to 0.54) or the use of ARBs (6.8% vs. 5.7%; odds ratio, 1.23; 95% CI, \n",
      "0.87 to 1.74).\n",
      "CONCLUSIONS\n",
      "Our study confirmed previous observations suggesting that underlying cardiovascu\n",
      "-lar disease is associated with an increased risk of in-hospital death among patients \n",
      "hospitalized with Covid-19. Our results did not confirm previous concerns regarding \n",
      "a potential harmful association of ACE inhibitors or ARBs with in-hospital death in \n",
      "this clinical context. (Funded by the William Harvey Distinguished Chair in Ad\n",
      "-vanced Cardiovascular Medicine at Brigham and WomenTMs Hospital.)\n",
      "ABSTRACT\n",
      "Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19Mandeep R. Mehra, M.D., Sapan\n",
      " S. Desai, M.D., Ph.D., \n",
      "SreyRam Kuy, M.D., M.H.S., Timothy\n",
      " D. Henry, M.D., and Amit\n",
      " N. Patel, M.D.\n",
      " \n",
      "Original Article\n",
      " n engl j med \n",
      "nejm.org 2The\n",
      " new england journal \n",
      "of medicine\n",
      "As the coronavirus disease 2019 \n",
      "(Covid-19) pandemic has spread around \n",
      "the globe, there has been growing recog\n",
      "-nition that persons with underlying increased \n",
      "cardiovascular risk may be disproportionately \n",
      "affected.\n",
      "1-3\n",
      " Several studies of case series have \n",
      "noted cardiac arrhythmias, cardiomyopathy, and \n",
      "cardiac arrest as terminal events in patients with \n",
      "Covid-19.\n",
      "1-4\n",
      " Higher incidences of cardiac arrhyth\n",
      "-mias, acute coronary syndromes, and heart fail\n",
      "-ureŒrelated events have also been reported during \n",
      "seasonal influenza outbreaks, which suggests that \n",
      "acute respiratory infections may result in activa\n",
      "-tion of coagulation pathways, proinflammatory \n",
      "effects, and endothelial cell dysfunction.\n",
      "5 In ad\n",
      "-dition, however, concern has been expressed that \n",
      "medical therapy for cardiovascular disease might \n",
      "specifically contribute to the severity of illness \n",
      "in patients with Covid-19.\n",
      "6,7\n",
      "Severe acute respiratory syndrome coronavirus \n",
      "2 (SARS-CoV-2), the causative agent of Covid-19, \n",
      "has been shown to establish itself in the host \n",
      "through the use of angiotensin-converting en\n",
      "-zyme 2 (ACE2) as its cellular receptor.\n",
      "8 ACE2 is \n",
      "a membrane-bound monocarboxypeptidase found \n",
      "ubiquitously in humans and expressed predomi\n",
      "-nantly in heart, intestine, kidney, and pulmonary \n",
      "alveolar (type II) cells.\n",
      "7,9\n",
      " Entry of SARS-CoV-2 \n",
      "into human cells is facilitated by the interaction \n",
      "of a receptor-binding domain in its viral spike \n",
      "glycoprotein ectodomain with the ACE2 receptor.\n",
      "10ACE2 is counterregulatory to the activity of \n",
      "angiotensin II generated through ACE1 and is \n",
      "protective against detrimental activation of the \n",
      "reninŒangiotensinŒaldosterone system. Angioten\n",
      "-sin II is catalyzed by ACE2 to angiotensin-(1Œ7), \n",
      "which exerts vasodilatory, antiinflammatory, an\n",
      "-tifibrotic, and antigrowth effects.\n",
      "11 It has been \n",
      "suggested that ACE inhibitors and angiotensin-\n",
      "receptor blockers (ARBs) may increase the expres\n",
      "-sion of ACE2, which has been shown in the heart \n",
      "in rats,\n",
      "12 and thereby may confer a predisposition \n",
      "to more severe infection and adverse outcomes \n",
      "during Covid-19.\n",
      "6,7\n",
      " Others have suggested that \n",
      "ACE inhibitors may counter the antiinflammatory \n",
      "effects of ACE2. However, in vitro studies have \n",
      "not shown direct inhibitory activity of ACE in\n",
      "-hibitors against ACE2 function.\n",
      "9,13\n",
      "Despite these uncertainties, some have rec\n",
      "-ommended cessation of treatment with ACE in\n",
      "-hibitors and ARBs in patients with Covid-19.\n",
      "6 However, several scientific societies, including \n",
      "the American Heart Association, the American \n",
      "College of Cardiology, the Heart Failure Society \n",
      "of America, and the Council on Hypertension of \n",
      "the European Society of Cardiology, have urged \n",
      "that these important medications should not be \n",
      "discontinued in the absence of clear clinical evi\n",
      "-dence of harm.\n",
      "14,15\n",
      " We therefore undertook a study \n",
      "to investigate the relationship between underlying \n",
      "cardiovascular disease and Covid-19 outcomes and \n",
      "to evaluate the association between cardiovascular \n",
      "drug therapy and mortality in this illness.\n",
      "Methods\n",
      "Data Source\n",
      "We analyzed deidentified data from the Surgical \n",
      "Outcomes Collaborative (Surgisphere), an interna\n",
      "-tional registry. Our analysis included data from \n",
      "169 hospitals located in 11 countries in Asia, \n",
      "Europe, and North America. The collaborative uses \n",
      "automated extraction of data from inpatient and \n",
      "outpatient electronic health records, supply-chain \n",
      "databases, and financial records, combined with \n",
      "point-of-care data entry for procedures. A manual \n",
      "data-entry process is used for quality assurance \n",
      "and validation. Data are collected through auto\n",
      "-mated data transfers that capture information \n",
      "from each health care entity at regular intervals \n",
      "on a prospective, ongoing basis. Verifiable source \n",
      "documentation for the data elements includes elec\n",
      "-tronic inpatient and outpatient medical records.\n",
      "Data acquisition is facilitated through the use \n",
      "of a standardized Health Level SevenŒcompliant \n",
      "data dictionary. After this data dictionary is har\n",
      "-monized with data from electronic health records, \n",
      "the majority of the data acquisition is completed \n",
      "with automated interfaces. The collected data \n",
      "sample from each health care entity is validated \n",
      "against financial records and external databas\n",
      "-es. All protected health information is stripped \n",
      "from each record before storage in a cloud-based \n",
      "data warehouse. The collaborative is compliant \n",
      "with the Agency for Healthcare Research and \n",
      "Quality guidelines for registries and the Food and \n",
      "Drug Administration guidance on real-world evi\n",
      "-dence. The collection and analysis of data in the \n",
      "registry have been deemed exempt from ethics \n",
      "review.\n",
      "Data Collection\n",
      "The collaborative registry was used as a resource \n",
      "to analyze data from all patients with polymerase-\n",
      " n engl j med \n",
      "nejm.org 3Cardiovascular Disease in Covid-19\n",
      "chain-reaction (PCR)Œproven Covid-19 who were \n",
      "admitted to the hospital between December 20, \n",
      "2019, and March 15, 2020, and who were re\n",
      "-corded in the registry as having either died in \n",
      "the hospital or survived to hospital discharge as \n",
      "of March 28, 2020. Data from the registry can be \n",
      "analyzed only after a patientTMs hospitalization is \n",
      "complete, and therefore our sample did not in\n",
      "-clude patients who were admitted to the hospital \n",
      "during this time window but were still hospital\n",
      "-ized at the end of it. Our sample also may have \n",
      "excluded some patients who had died or were \n",
      "discharged by March 28 but whose discharge \n",
      "status had not yet been recorded by the hospital.\n",
      "The presence in the record of a positive labo\n",
      "-ratory finding confirming SARS-CoV-2 infection \n",
      "was used for classifying a patient as positive for \n",
      "Covid-19. A positive laboratory finding for SARS-\n",
      "CoV-2 was defined as a positive result on high-\n",
      "throughput sequencing or real-time reverse-tran\n",
      "-scriptaseŒPCR (RT-PCR) assay of nasal or \n",
      "pharyngeal swab specimens. At each site, Covid-19 \n",
      "was diagnosed on the basis of the World Health \n",
      "Organization guidance.\n",
      "16 Patients who did not \n",
      "undergo testing, had no record of testing in the \n",
      "collaborative database, or had a negative test \n",
      "were not included in the present study. For this \n",
      "study, only one positive test was necessary for \n",
      "the patient to be included in the analysis.\n",
      "Data on patientsTM demographic characteris\n",
      "-tics, coexisting conditions (based on codes from \n",
      "the \n",
      "International Classification of Diseases, 10th Revi\n",
      "-sion, Clinical Modification\n",
      "), and cardiovascular drug \n",
      "therapy were included in this analysis. Clinical \n",
      "information included age, sex, continent of ori\n",
      "-gin, and underlying coexisting conditions as \n",
      "noted in either the inpatient or the outpatient \n",
      "electronic health record. Coexisting conditions \n",
      "included chronic obstructive pulmonary disease \n",
      "(COPD), an immunosuppressed condition (glu\n",
      "-cocorticoid use, a preexisting immunologic con\n",
      "-dition, or ongoing chemotherapy in patients \n",
      "with cancer), current or remote history of smok\n",
      "-ing, and a history of hypertension, diabetes mel\n",
      "-litus, hyperlipidemia, or underlying cardiovascu\n",
      "-lar disease (including coronary artery disease, \n",
      "heart failure, and cardiac arrhythmia). Cardio\n",
      "-vascular drug therapy recorded at the time of \n",
      "hospital admission was also included, including \n",
      "any antiplatelet therapy, use of insulin or other \n",
      "hypoglycemic agents, beta-blockers, statins, ARBs, \n",
      "and ACE inhibitors.\n",
      "All the authors reviewed the manuscript and \n",
      "vouch for the accuracy and completeness of the \n",
      "data provided.\n",
      "Statistical Analysis\n",
      "The primary analysis was an evaluation of the \n",
      "relationship of preexisting cardiovascular dis\n",
      "-ease and drug therapy with the end point of in-\n",
      "hospital death while controlling for confound\n",
      "-ers, including demographic characteristics and \n",
      "coexisting conditions. Categorical variables are \n",
      "shown as frequencies and percentages, and con\n",
      "-tinuous variables as means and standard devia\n",
      "-tions. Independent sample t-tests were complet\n",
      "-ed, and point differences with 95% confidence \n",
      "intervals are reported for all comparisons be\n",
      "-tween variables. Multiple imputation for missing \n",
      "values was not possible because for disease and \n",
      "drug variables there were no codes to indicate \n",
      "that data were missing; if the patientTMs elec\n",
      "-tronic health record did not include information \n",
      "on a clinical characteristic, such as hyperlipid\n",
      "-emia or the use of beta-blockers, it was assumed \n",
      "that that characteristic was not present.\n",
      "A multivariable logistic-regression analysis \n",
      "was performed to ascertain the effects of age, \n",
      "race, coexisting conditions (coronary artery dis\n",
      "-ease, congestive heart failure, cardiac arrhyth\n",
      "-mia, diabetes mellitus, COPD, current smoking, \n",
      "former smoking, hypertension, immunocompro\n",
      "-mised state, and hyperlipidemia), hospital loca\n",
      "-tion (according to country), and medications \n",
      "(ACE inhibitors, ARBs, beta-blockers, antiplate\n",
      "-let agents, statins, insulin, and oral hypoglyce\n",
      "-mic agents) on the likelihood of in-hospital \n",
      "death. Linearity of the continuous variables with \n",
      "respect to the logit of the dependent variable was \n",
      "confirmed. Odds ratios and corresponding 95% \n",
      "confidence intervals were calculated. Separate \n",
      "age- and sex-adjusted analyses were also per\n",
      "-formed. The 95% confidence intervals have not \n",
      "been adjusted for multiple testing and should \n",
      "not be used to infer definitive effects.\n",
      "On the basis of the results of the initial \n",
      "analyses, additional analyses were performed to \n",
      "examine the robustness of the estimates initially \n",
      "obtained. Analyses according to continent of ori\n",
      "-gin as well as country classification (as either high \n",
      "income or lowŒmiddle income) were performed. \n",
      "A tipping-point analysis (an analysis that shows \n",
      "the effect size and prevalence of an unmeasured \n",
      "confounder that could shift the upper boundary \n",
      " n engl j med \n",
      "nejm.org 4The\n",
      " new england journal \n",
      "of medicine\n",
      "of the confidence interval toward null) was per\n",
      "-formed. In addition, we sought to determine \n",
      "whether the effect of ACE inhibitors and statins \n",
      "noted in the overall study was also seen when \n",
      "the analysis was confined to a subgroup of pa\n",
      "-tients who might have an indication for these \n",
      "agents. Thus, the association of ACE inhibitor \n",
      "use with in-hospital death was examined in the \n",
      "subgroup of patients with hypertension, and the \n",
      "association of statin use with in-hospital death \n",
      "was examined in the subgroup of patients with \n",
      "hyperlipidemia, with the use of age- and sex-\n",
      "adjusted logistic-regression analysis. All statistical \n",
      "analyses were performed with R software, version \n",
      "3.6.3 (R Foundation for Statistical Computing), \n",
      "and SPSS Statistics software, version 26 (IBM).\n",
      "Results\n",
      "Patients\n",
      "Our study population included 8910 hospitalized \n",
      "patients from 169 hospitals who had Covid-19, \n",
      "who were admitted between December 20, 2019, \n",
      "and March 15, 2020, and who completed their \n",
      "hospital course (discharged alive or died) by March \n",
      "28, 2020. Patients who were hospitalized during \n",
      "this time without a completed course could not \n",
      "be included in the analysis. Our sample was \n",
      "made up of 1536 patients (17.2%) from North \n",
      "America, 5755 (64.6%) from Europe, and 1619 \n",
      "(18.2%) from Asia (details of the study popula\n",
      "-tion according to continent, country, and num\n",
      "-ber of hospitals are provided in Table S1 in the \n",
      "Supplementary Appendix, available with the full \n",
      "text of this article at NEJM.org). The mean (±SD) \n",
      "age was 49±16 years (16.5% of the patients were \n",
      ">65 years of age), 40.0% of the patients were \n",
      "women, 63.5% were white, 7.9% were black, 6.3% \n",
      "were Hispanic, and 19.3% were Asian.\n",
      "With respect to cardiovascular risk factors, \n",
      "30.5% of the patients had hyperlipidemia, 26.3% \n",
      "had hypertension, 14.3% had diabetes mellitus, \n",
      "16.8% were former smokers, and 5.5% were cur\n",
      "-rent smokers. Preexisting cardiovascular disease \n",
      "in this sample included coronary artery disease \n",
      "(present in 11.3% of the patients), a history of con\n",
      "-gestive heart failure (2.1%), and a history of cardiac \n",
      "arrhythmia (3.4%). Other coexisting conditions \n",
      "included COPD (in 2.5% of the patients) and an \n",
      "underlying immunosuppressed condition (2.8%). \n",
      "Medical therapy included ACE inhibitors (8.6% \n",
      "of the patients), ARBs (6.2%), statins (9.7%), \n",
      "beta-blockers (5.9%), and antiplatelet agents (3.3%). \n",
      "Insulin was used in 3.4% of the patients, and \n",
      "other hypoglycemic agents were used in 9.6%. \n",
      "The mean length of hospital stay was 10.7±2.7 \n",
      "days, with an overall in-hospital mortality of \n",
      "5.8% (515 of 8910 patients) in this population of \n",
      "patients with completed outcomes. Of the pa\n",
      "-tients who had been admitted to an intensive care \n",
      "unit (ICU) at any time during their hospitaliza\n",
      "-tion, 24.7% died, as compared with 4.0% of the \n",
      "patients who had not been admitted to an ICU.\n",
      "Analysis of Survivors as Compared \n",
      " with Nonsurvivors\n",
      "Table\n",
      " 1 shows the distribution of demographic \n",
      "characteristics and coexisting conditions among \n",
      "survivors and nonsurvivors, along with the be\n",
      "-tween-group differences and 95% confidence in\n",
      "-tervals. Nonsurvivors were older, more likely to be \n",
      "white, and more often men, and they had a \n",
      "greater prevalence of diabetes mellitus, hyperlip\n",
      "-idemia, coronary artery disease, heart failure, \n",
      "and cardiac arrhythmias. Patients who died were \n",
      "also more likely to have had COPD and a history \n",
      "of current smoking. Among medications, ACE in\n",
      "-hibitors and statins were more commonly used by \n",
      "survivors than by nonsurvivors (Table\n",
      " 2), whereas \n",
      "no association between survival and the use of \n",
      "ARBs was found. The length of hospital stay dif\n",
      "-fered between survivors and nonsurvivors (10.5±2.5 \n",
      "days vs. 7.5±2.8 days). When the data were ana\n",
      "-lyzed according to age decile, continent, or in\n",
      "-come category of the country in which the hos\n",
      "-pital was located (high income or lowŒmiddle \n",
      "income), the results were similar (Fig. S1 and \n",
      "Tables S2 and S3).\n",
      "Multivariable Logistic-Regression Analysis\n",
      "A multivariable logistic-regression model was \n",
      "developed. Independent predictors of in-hospital \n",
      "death and their corresponding odds ratios and \n",
      "95% confidence intervals are shown in Figure\n",
      " 1. \n",
      "An age greater than 65 years, coronary artery \n",
      "disease, congestive heart failure, cardiac arrhyth\n",
      "-mia, COPD, and current smoking were associat\n",
      "-ed with a higher risk of in-hospital death. Fe\n",
      "-male sex, the use of ACE inhibitors, and the use \n",
      "of statins were associated with a better chance \n",
      "of survival to hospital discharge, with no associa\n",
      "-tion found for the use of ARBs. For female sex, \n",
      " n engl j med \n",
      "nejm.org 5Cardiovascular Disease in Covid-19\n",
      "the odds ratio for dying in the hospital was 0.79 \n",
      "(95% confidence interval [CI], 0.65 to 0.95); for \n",
      "ACE inhibitor use, the odds ratio was 0.33 (95% \n",
      "CI, 0.20 to 0.54); and for statin use, the odds \n",
      "ratio was 0.35 (95% CI, 0.24 to 0.52). For ARB \n",
      "use, the odds ratio was 1.23 (95% CI, 0.87 to \n",
      "1.74). The presence or absence of an immuno\n",
      "-suppressed condition, the race or ethnic group, \n",
      "and the presence or absence of hyperlipidemia \n",
      "or diabetes mellitus were not independent pre\n",
      "-dictors of death in the hospital. The analyses \n",
      "according to continent and according to the in\n",
      "-come category of the country (high or lowŒmiddle) \n",
      "were consistent with the overall results (Tables \n",
      "S4 and S5). Data from the age- and sex-adjusted \n",
      "multivariable logistic-regression analyses are \n",
      "shown in Table S6.\n",
      "Table 1.\n",
      " Demographic Characteristics and Coexisting Conditions among Survivors and Nonsurvivors of Covid-19.*\n",
      "Characteristic or Condition\n",
      "Survivors (N = 8395)Nonsurvivors (N = 515)Difference (95% CI)ƒ\n",
      "Age S yr\n",
      "48.7±16.655.8±15.1 7.1 ( 8.4 to  5.7)\n",
      "Age >65 yr S no. (%)\n",
      "1327 (15.8)\n",
      "147 (28.5)\n",
      " 12.7 ( 16.0 to  9.4)\n",
      "Female sex S no. (%)\n",
      "3392 (40.4)\n",
      "179 (34.8)\n",
      "5.6 (1.3 to 10.0)\n",
      "Race or ethnic group S no. (%)⁄\n",
      "White5306 (63.2)\n",
      "351 (68.2)\n",
      " 5.0 ( 9.1 to  0.8)\n",
      "Black672 (8.0)\n",
      "34 (6.6)\n",
      "1.4 ( 0.8 to 3.6)\n",
      "Hispanic529 (6.3)\n",
      "32 (6.2)\n",
      "0.1 ( 2.0 to 2.3)\n",
      "Asian1637 (19.5)\n",
      "84 (16.3)\n",
      "3.2 ( 0.2 to 6.5)\n",
      "Native American\n",
      "34 (0.4)\n",
      "1 (0.2)\n",
      "0.2 ( 0.3 to 0.8)\n",
      "Other219 (2.6)\n",
      "13 (2.5)\n",
      "0.1 ( 1.4 to 1.4)\n",
      "Coexisting conditions S no. (%)\n",
      "Coronary artery disease\n",
      "907 (10.8)\n",
      "103 (20.0)\n",
      " 9.2 ( 12.8 to  5.7)\n",
      "Congestive heart failure\n",
      "160 (1.9)\n",
      "29 (5.6)\n",
      " 3.7 ( 5.8 to  1.8)\n",
      "Cardiac arrhythmia269 (3.2)\n",
      "35 (6.8)\n",
      " 3.6 ( 5.8 to  1.4)\n",
      "Diabetes mellitus\n",
      "1175 (14.0)\n",
      "97 (18.8)\n",
      " 4.8 ( 8.3 to  1.3)\n",
      "Hypertension2216 (26.4)\n",
      "130 (25.2)\n",
      "1.2 ( 2.8 to 5.1)\n",
      "Hyperlipidemia2535 (30.2)\n",
      "180 (35.0)\n",
      " 4.8 ( 9.0 to  0.5)\n",
      "COPD193 (2.3)\n",
      "32 (6.2)\n",
      " 3.9 ( 6.1 to  1.8)\n",
      "Current smoker\n",
      "445 (5.3)\n",
      "46 (8.9)\n",
      " 3.6 ( 6.2 to  1.1)\n",
      "Former smoker\n",
      "1410 (16.8)\n",
      "83 (16.1)\n",
      "0.7 ( 2.6 to 4.0)\n",
      "Immunosuppressed condition\n",
      "227 (2.7)\n",
      "22 (4.3)\n",
      " 1.6 ( 3.4 to 0.2)\n",
      "* \n",
      "PlusŒminus values are means ±SD. The 95% confidence intervals (CIs) have not been adjusted for multiple testing and should not be used to infer definitive effects. COPD denotes chronic obstructive pulmonary disease, and Covid-19 coro-navirus disease 2019.ƒ \n",
      "For mean age, the difference is given in years; for all other characteristics, the difference is given in percentage points.⁄ \n",
      "Race and ethnic group were reported by the patient.Table 2.\n",
      " Cardiovascular Drug Therapy at Hospitalization among Survivors \n",
      " and Nonsurvivors of Covid-19.*\n",
      "Drug Class\n",
      "Survivors (N = 8395)Nonsurvivors (N = 515)Difference (95% CI)\n",
      "number (percent)\n",
      "percentage points\n",
      "ACE inhibitor\n",
      "754 (9.0)\n",
      "16 (3.1)\n",
      "5.9 (4.3 to 7.5)\n",
      "ARB518 (6.2)\n",
      "38 (7.4)\n",
      " 1.2 ( 3.5 to 1.1)\n",
      "Beta-blocker497 (5.9)\n",
      "28 (5.4)\n",
      "0.5 ( 1.6 to 2.6)\n",
      "Antiplatelet282 (3.4)\n",
      "13 (2.5)\n",
      "0.8 ( 0.6 to 2.2)\n",
      "Statin824 (9.8)\n",
      "36 (7.0)\n",
      "2.8 (0.5 to 5.1)\n",
      "Insulin279 (3.3)\n",
      "23 (4.5)\n",
      " 1.2 ( 3.0 to 0.7)\n",
      "Other hypoglycemic agent792 (9.4)\n",
      "59 (11.5)\n",
      " 2.1 ( 4.9 to 0.8)\n",
      "* \n",
      "The 95% confidence intervals have not been adjusted for multiple testing and should not be used to infer definitive effects. ACE denotes angiotensin-converting enzyme, and ARB angiotensin-receptor blocker. n engl j med \n",
      "nejm.org 6The\n",
      " new england journal \n",
      "of medicine\n",
      "Additional Analyses\n",
      "In the tipping-point analysis to assess the poten\n",
      "-tial effect of an unmeasured confounder, it was \n",
      "estimated that a hypothetical unobserved binary \n",
      "confounder with a prevalence of 10% in the study \n",
      "population would need to have an odds ratio of \n",
      "at least 10 in order for the observed associations \n",
      "for either ACE inhibitors or statins to have 95% \n",
      "confidence intervals crossing the odds ratio \n",
      "boundary of 1.0 (Table S7). We also separately \n",
      "examined the interaction of ACE inhibitor use \n",
      "with mortality in the subgroup with hyperten\n",
      "-sion and the interaction of statin use with mor\n",
      "-tality in the subgroup with hyperlipidemia. These \n",
      "analyses, shown in Table S8, are consistent with \n",
      "the results of the primary analysis.\n",
      "Discussion\n",
      "Our investigation confirms previous reports of \n",
      "the independent relationship of older age, under\n",
      "-lying cardiovascular disease (coronary artery dis\n",
      "-ease, heart failure, and cardiac arrhythmias), cur\n",
      "-rent smoking, and COPD with death in Covid-19. \n",
      "Our results also suggest that women are propor\n",
      "-tionately more likely than men to survive the \n",
      "infection. Neither harmful nor beneficial asso\n",
      "-ciations were noted for antiplatelet therapy, beta-\n",
      "blockers, or hypoglycemic therapy. It is important \n",
      "to note that we were not able to confirm previous \n",
      "concerns regarding a potential harmful associa\n",
      "-tion of either ACE inhibitors or ARBs with in-\n",
      "hospital mortality in this clinical context.\n",
      "In viral infections such as influenza, older \n",
      "age is associated with an increased risk of car\n",
      "-diovascular events and death.\n",
      "5 In the 2003 epi\n",
      "-demic of severe acute respiratory syndrome \n",
      "(SARS, caused by SARS-CoV-1 infection), sex \n",
      "differences in the risk of death similar to those \n",
      "we observed were noted.\n",
      "17 Women have stronger \n",
      "innate and adaptive immunity and greater resis\n",
      "-tance to viral infections than men.\n",
      "18 In animal \n",
      "models of SARS-CoV-1 infection, higher suscep\n",
      "-tibility of male mice to SARS-CoV-1 and greater \n",
      "accumulation of macrophages and neutrophils \n",
      "in the lungs have been described.\n",
      "19 Ovariectomy \n",
      "or the use of estrogen-receptor antagonists \n",
      "increased mortality from SARS-CoV-1 infection \n",
      "in female animals. Furthermore, the difference in \n",
      "risk between the sexes increased with advancing \n",
      "age.\n",
      "19 These findings may support the observa\n",
      "-tion in our investigation that suggested an as\n",
      "-sociation between survival and female sex, inde\n",
      "-pendent of older age.\n",
      "Infection with SARS-CoV-2 is a mild disease \n",
      "in most people, but in some the disease pro\n",
      "-gresses to a severe respiratory illness character\n",
      "-ized by a hyperinflammatory syndrome, multi\n",
      "-organ dysfunction, and death.\n",
      "20 In the lung, the \n",
      "viral spike glycoprotein of SARS-CoV-2 interacts \n",
      "with cell-surface ACE2, and the virus is internal\n",
      "-ized by endocytosis. The endocytic event up-\n",
      "regulates the activity of ADAM metallopeptidase \n",
      "domain 17 (ADAM17), which cleaves ACE2 from \n",
      "the cell membrane, resulting in a loss of ACE2-\n",
      "mediated protection against the effects of activa\n",
      "-Figure 1.\n",
      " Independent Predictors of In-Hospital Death from Multivariable Logistic-Regression Analysis.\n",
      "Numbers and percentages of patients with each risk factor who died (risk factor present) and of patients without each risk factor who \n",
      "died (risk factor absent) are shown. The 95% confidence intervals (CIs) of the odds ratios have not been adjusted for multiple testing \n",
      "and should not be used to infer definitive effects. ACE denotes angiotensin-converting enzyme, ARB angiotensin-receptor blocker, and \n",
      "COPD chronic obstructive pulmonary disease.\n",
      "       ˇˇˇ  –•    ˇ‡   ƒ...ˇˇƒ—• ⁄—ˇ‡ ˆ –...ˇˇ–ˆ•– €ˇ‡   ˆ...ˇˇ–ƒ•ƒƒˆˇ‡ € ƒ...€ •€— ˇ‡— €...–⁄•ˆˆ ˇ‡  ⁄...– •⁄  ˇ‡€ ƒ...–– •ˆ––—ˇ‡  –...€⁄ •⁄   ˇ‡ˆ  ...€⁄–•⁄ ⁄ˆˇ‡ˆ  ...€ —•⁄€ —ˇ‡ˆ  ...€——•⁄ € ˇ‡   ...  —–ˇ‡    ‹ƒ € ...ˆ‹  —ˆ...⁄‹– ˆ ...ƒ €⁄ˇ‡   ƒ‹  —ˆˇ‡  ––‹ƒ ⁄ ...ƒ — ˇ‡ƒ   ‹€ € ...—‹  ––ˇ‡  ƒ ‹  ˆ€...  ƒ–ˇ‡  ⁄  –ˆˇ‡  ƒ€‹  ˆƒ...    n engl j med \n",
      "nejm.org 7Cardiovascular Disease in Covid-19\n",
      "tion of the tissue reninŒangiotensinŒaldosterone \n",
      "system while mediating the release of proin\n",
      "-flammatory cytokines into the circulation.\n",
      "21 The \n",
      "stress of critical illness and inflammation may \n",
      "unite in destabilizing preexisting cardiovascular \n",
      "illness. Vascular endothelial cell dysfunction, in\n",
      "-flammation-associated myocardial depression, \n",
      "stress cardiomyopathy, direct viral infection of \n",
      "the heart and its vessels, or the host response may \n",
      "cause or worsen heart failure, demand-related isch\n",
      "-emia, and arrhythmias.\n",
      "22 These factors may under\n",
      "-lie the observed associations between cardiovascu\n",
      "-lar disease and death in Covid-19.\n",
      "In our analyses, use of either ACE inhibitors \n",
      "or statins was associated with better survival \n",
      "among patients with Covid-19. However, these as\n",
      "-sociations should be considered with extreme cau\n",
      "-tion. Because our study was not a randomized, \n",
      "controlled trial, we cannot exclude the possibility \n",
      "of confounding. In addition, we examined rela\n",
      "-tionships between many variables and in-hospi\n",
      "-tal death, and no primary hypothesis was pre\n",
      "-specified; these factors increased the probability \n",
      "of chance associations being found. Therefore, a \n",
      "cause-and-effect relationship between drug ther\n",
      "-apy and survival should not be inferred. These \n",
      "data also offer no information concerning the \n",
      "potential effect of initiation of ACE inhibitor or \n",
      "statin therapy in patients with Covid-19 who do \n",
      "not have an appropriate indication for these \n",
      "medications. Randomized clinical trials evaluat\n",
      "-ing the role of ACE inhibitors and statins will be \n",
      "necessary before any conclusion can be reached \n",
      "regarding a potential benefit of these agents in \n",
      "patients with Covid-19.\n",
      "In this multinational observational study in\n",
      "-volving patients hospitalized with Covid-19, we \n",
      "confirmed previous observations suggesting that \n",
      "underlying cardiovascular disease is independently \n",
      "associated with an increased risk of in-hospital \n",
      "death. We were not able to confirm previous con\n",
      "-cerns regarding a potential harmful association \n",
      "of ACE inhibitors or ARBs with in-hospital mor\n",
      "-tality in this clinical context.\n",
      "Supported by the William Harvey Distinguished Chair in \n",
      "Advanced Cardiovascular Medicine at Brigham and WomenTMs \n",
      "Hospital. The development and maintenance of the Surgical \n",
      "Outcomes Collaborative database was funded by Surgisphere.\n",
      "Disclosure forms provided by the authors are available with \n",
      "the full text of this article at NEJM.org.\n",
      "References\n",
      "1. Ruan Q, Yang K, Wang W, Jiang L, \n",
      "Song J. Clinical predictors of mortality \n",
      "due to COVID-19 based on an analysis of \n",
      "data of 150 patients from Wuhan, China. \n",
      "Intensive Care Med 2020 March 3 (Epub \n",
      "ahead of print).\n",
      "2. Shi S, Qin M, Shen B, et al. Associa\n",
      "-tion of cardiac injury with mortality in \n",
      "hospitalized patients with COVID-19 in \n",
      "Wuhan, China. JAMA Cardiol 2020 March \n",
      "25 (Epub ahead of print).\n",
      "3. Guo T, Fan Y, Chen M, et al. Cardio\n",
      "-vascular implications of fatal outcomes of \n",
      "patients with coronavirus disease 2019 \n",
      "(COVID-19). JAMA Cardiol 2020 March 27 \n",
      "(Epub ahead of print).\n",
      "4. Arentz M, Yim E, Klaff L, et al. Char\n",
      "-acteristics and outcomes of 21 critically ill \n",
      "patients with COVID-19 in Washington \n",
      "State. JAMA 2020 March 19 (Epub ahead \n",
      "of print).\n",
      "5. Nguyen JL, Yang W, Ito K, Matte TD, \n",
      "Shaman J, Kinney PL. Seasonal influenza \n",
      "infections and cardiovascular disease \n",
      "mortality. JAMA Cardiol 2016;\n",
      " \n",
      "1:\n",
      " \n",
      "274-81.\n",
      "6. Fang L, Karakiulakis G, Roth M. Are \n",
      "patients with hypertension and diabetes \n",
      "mellitus at increased risk for COVID-19 \n",
      "infection? Lancet Respir Med 2020;\n",
      " \n",
      "8(4):\n",
      " e21.\n",
      "7. Nicin L, Abplanalp WT, Mellentin H, \n",
      "et al. Cell type-specific expression of the \n",
      "putative SARS-CoV-2 receptor ACE2 in hu\n",
      "-man hearts. Eur Heart J 2020 April 15 \n",
      "(Epub ahead of print).\n",
      "8. Hoffmann M, Kleine-Weber H, Schro\n",
      "-eder S, et al. SARS-CoV-2 cell entry de\n",
      "-pends on ACE2 and TMPRSS2 and is \n",
      "blocked by a clinically proven protease \n",
      "inhibitor. Cell 2020;\n",
      " 181(2):\n",
      " 271.e8-280.e8.\n",
      "9. Rice GI, Thomas DA, Grant PJ, Turner \n",
      "AJ, Hooper NM. Evaluation of angioten\n",
      "-sin-converting enzyme (ACE), its homo\n",
      "-logue ACE2 and neprilysin in angiotensin \n",
      "peptide metabolism. Biochem J 2004;\n",
      " \n",
      "383:\n",
      " 45-51.\n",
      "10.\n",
      " Walls AC, Park YJ, Tortorici MA, Wall \n",
      "A, McGuire AT, Veesler D. Structure, \n",
      "function, and antigenicity of the SARS-\n",
      "CoV-2 spike glycoprotein. Cell 2020;\n",
      " 181(2):\n",
      " 281.e6-292.e6.\n",
      "11.\n",
      " Li XC, Zhang J, Zhuo JL. The vasopro\n",
      "-tective axes of the renin-angiotensin sys\n",
      "-tem: physiological relevance and thera\n",
      "-peutic implications in cardiovascular, \n",
      "hypertensive and kidney diseases. Phar\n",
      "-macol Res 2017;\n",
      " 125:\n",
      " 21-38.\n",
      "12.\n",
      " Ferrario CM, Jessup J, Chappell MC, et \n",
      "al. Effect of angiotensin-converting en\n",
      "-zyme inhibition and angiotensin II recep\n",
      "-tor blockers on cardiac angiotensin-con\n",
      "-verting enzyme 2. Circulation 2005;\n",
      " \n",
      "111:\n",
      " 2605-10.\n",
      "13.\n",
      " Patel AB, Verma A. COVID-19 and \n",
      "angiotensin-converting enzyme inhibi\n",
      "-tors and angiotensin receptor blockers: \n",
      "what is the evidence? JAMA 2020 March \n",
      "24 (Epub ahead of print).\n",
      "14.\n",
      " American College of Cardiology. \n",
      "HFSA/ACC/AHA statement addresses \n",
      "concerns re: using RAAS antagonists in \n",
      "COVID-19. March 17, 2020 (https://www\n",
      " .acc\n",
      " .org/\n",
      " latest\n",
      " - in\n",
      " - cardiology/\n",
      " articles/\n",
      " 2020/\n",
      " 03/\n",
      " 17/\n",
      " 08/\n",
      " 59/\n",
      " hfsa\n",
      " - acc\n",
      " - aha\n",
      " - statement\n",
      " - addresses\n",
      " - concerns\n",
      " - re\n",
      " - using\n",
      " - raas\n",
      " - antagonists\n",
      " - in\n",
      " - covid\n",
      " - 19).\n",
      "15.\n",
      " European Society of Cardiology. Posi\n",
      "-tion statement of the ESC Council on Hy\n",
      "-pertension on ACE-inhibitors and angio\n",
      "-tensin receptor blockers. March 13, 2020 \n",
      "(https://www\n",
      " .escardio\n",
      " .org/\n",
      " Councils/\n",
      " Council\n",
      " - on - Hypertension\n",
      " - (CHT)/\n",
      " News/\n",
      " position\n",
      " - statement\n",
      " - of - the\n",
      " - esc\n",
      " - council\n",
      " - on - hypertension\n",
      " - on - ace\n",
      " - inhibitors\n",
      " - and\n",
      " - ang).\n",
      "16.\n",
      " World Health Organization. Clinical \n",
      "management of severe acute respiratory \n",
      "infection (SARI) when COVID-19 disease \n",
      "is suspected: interim guidance. March 13, \n",
      "2020 (https://www\n",
      " .who\n",
      " .int/\n",
      " docs/\n",
      " default\n",
      " - source/\n",
      " coronaviruse/\n",
      " clinical\n",
      " - management\n",
      " - of\n",
      " - novel\n",
      " - cov\n",
      " .pdf).\n",
      "17.\n",
      " Karlberg J, Chong DSY, Lai WYY. Do \n",
      "men have a higher case fatality rate of se\n",
      "-vere acute respiratory syndrome than \n",
      "women do? Am J Epidemiol 2004;\n",
      " \n",
      "159:\n",
      " \n",
      "229-\n",
      "31.\n",
      " n engl j med \n",
      "nejm.org 8The\n",
      " new england journal \n",
      "of medicine\n",
      "18.\n",
      " Klein SL, Flanagan KL. Sex differenc\n",
      "-es in immune responses. Nat Rev Immu\n",
      "-nol 2016;\n",
      " 16:\n",
      " 626-38.\n",
      "19.\n",
      " Channappanavar R, Fett C, Mack M, \n",
      "Ten Eyck PP, Meyerholz DK, Perlman S. \n",
      "Sex-based differences in susceptibility to \n",
      "severe acute respiratory syndrome coro\n",
      "-navirus infection. J Immunol 2017;\n",
      " \n",
      "198:\n",
      " 4046-53.\n",
      "20.\n",
      " Siddiqi HK, Mehra MR. COVID-19 ill\n",
      "-ness in native and immunosuppressed \n",
      "states: a clinical-therapeutic staging propos\n",
      "-al. J Heart Lung Transplant 2020;\n",
      " \n",
      "39:\n",
      " \n",
      "405-7.\n",
      "21.\n",
      " Wang K, Gheblawi M, Oudit GY. An\n",
      "-giotensin converting enzyme 2: a double-\n",
      "edged sword. Circulation 2020 March 26 \n",
      "(Epub ahead of print).\n",
      "22.\n",
      " Mehra MR, Ruschitzka F. COVID-19 \n",
      "illness and heart failure: a missing link? \n",
      "JACC Heart Fail (in press).\n",
      "Copyright © 2020 Massachusetts Medical Society.\n"
     ]
    }
   ],
   "source": [
    "data=textacy.preprocessing.remove.remove_accents(data)\n",
    "print(data)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 69,
   "metadata": {},
   "outputs": [],
   "source": [
    "def read_pdf_extract_text(path='data/1.pdf'):\n",
    "    pdfFileObj = open(path, 'rb') \n",
    "\n",
    "    # creating a pdf Reader object \n",
    "    pdfReader = PyPDF2.PdfFileReader(pdfFileObj)\n",
    "    pdf_text = ''\n",
    "    print(pdfReader.numPages)\n",
    "    for i in range(0, pdfReader.numPages):\n",
    "        pageObj = pdfReader.getPage(i)\n",
    "        page = pageObj.extractText()\n",
    "        pdf_text = pdf_text + ' ' + page \n",
    "    \n",
    "    text = ftfy.fix_text(pdf_text)\n",
    "    data = ftfy.fix_encoding(text)\n",
    "    data=textacy.preprocessing.remove.remove_punctuation(data, marks='\\n')\n",
    "    data=textacy.preprocessing.normalize.normalize_whitespace(data)\n",
    "    data=textacy.preprocessing.normalize.normalize_unicode(data)\n",
    "    data=textacy.preprocessing.remove.remove_accents(data)\n",
    "    \n",
    "    return pdf_text"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 72,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "data/1.pdf\n",
      "7\n",
      "data/2.pdf\n",
      "8\n",
      "data/3.pdf\n",
      "10\n",
      "data/4.pdf\n",
      "24\n"
     ]
    }
   ],
   "source": [
    "paths = ['data/1.pdf','data/2.pdf','data/3.pdf','data/4.pdf']\n",
    "i = 0\n",
    "for path in paths:\n",
    "    i = i + 1\n",
    "    print(path)\n",
    "    d = read_pdf_extract_text(path)\n",
    "    import pathlib\n",
    "    output_path = 'data/' + str(i) + '.txt'\n",
    "    pathlib.Path(output_path).write_text(d)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 56,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "34451"
      ]
     },
     "execution_count": 56,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python [conda env:py37] *",
   "language": "python",
   "name": "conda-env-py37-py"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.7.8"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 4
}
